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ROLE OF NEWLY SYNTHESIZED STEROID HORMONE ANTAGONISTS
IN ADRENOCORTICOSTEROID HORMONE-INDUCED HYPERTENSION
ABSTRACT

A dissertation in partial fulfillment of the requirements for
the degree of Doctor of Philosophy at the Virginia Commonwealth University

Justicia Opoku-Edusei, Ph.D.
Medical College of Virginia--Virginia Commonwealth University,
Major Director:

1990

Mohammed Y. Kalimi, Ph.D.

Excess adrenocorticosteroid hormones such as glucocorticoids and
mineralocorticoids is well known to induce hypertension in several animal species
as well as in humans. Therefore, the development of potent and specific
glucocorticoid and mineralocorticoid antagonists with antihypertensive effects is
clinically necessary. steroid hormone antagonists being used therapeutically
present serious endocrinology side effects such as the widely used
antimineralocorticoid, spironolactone. The antiglucocorticoids available so far
have been active only ill vitro or only weakly ill vivo. Recently, three new exciting
adrenocorticosteroid hormone antagonists have been synthesized. RU

486

is a

potent antiglucocorticoid (and antiprogesterone with potential as an abortifacient),
RU

26752

and mespirenone, are novel mineralocorticoid antagonists. I studied

x

the antihypertensive effect of RU

486 , RU 26752

and mespirenone in Sprague

Dawley rats with dexamethasone- or aldosterone-induced hypertension. In
addition, the effect of these antagonists on the hypertension developed by genetic
model, spontaneously hypertensive rats (SHR) were also studied. The SHR is the
closest animal model to human essential hypertension and it is believed that
adrenocorticosteroid hormones are involved in the induction and maintenance of
the hypertension. The results obtained from my studies showed that RU

486

administered simultaneously with dexamethasone prevented the hypertension
induced by dexamethasone treatment. However, RU

486

had no effect on

mineralocorticoid-induced hypertension. The administration of the
antimineralocorticoid RU

26752

or mespirenone in combination with aldosterone

successfully presented aldosterone-induced hypertension but not dexamethasone
induced hypertension. Surprisingly, RU

486

caused a significant increase in the

blood pressure of the SHR whilst mespirenone caused a slight decrease in blood
pressure as compared to control SHR.
The effect of these anti hormones on body/organ weights, fluid intake and
urinary output was observed.

Morphologically examination of the heart and

kidney showed no abnormalities with treatment. These results suggest that 1) RU

486 is specific in preventing dexamethasone-induced hypertension; 2) RU 26752
and mespirenone are successful in preventing aldosterone-induced hypertension
and

3)

mineralocorticoids may be involved in the development and maintenance

of hypertension in the SHR.

INTRODUCfION

The adrenal cortex has long been known to be involved in the pathogenesis
of hypertension. It has been observed that hypertension cannot be produced or
sustained without the adrenal cortex as bilateral adrenalectomy without steroid
hormonal replacement leads to decreased blood pressure which causes circulatory
collapse and eventuaIJy death (1, 14). On the other hand, it is known that
adrenocortical hyper-reactivity leads to an increase in the blood pressure (2,3).
Several clinical and experimental studies indicate that adrenal steroids play an
important role in the development and/or maintenance of various types of
hypertension (4). Steroid hormones produced by the adrenal cortex are broadly
classified into two categories, namely, glucocorticoids and mineralocorticoids. The
exogenous administration of high amounts of glucocorticoid agonists such as
dexamethasone (5-7) and mineralocorticoid agonist such as aldosterone (8-10)
induce hypertension in several animal species as weIJ as in humans. In addition,
adrenal hyperactivity is associated directly with hypertension in three disorders in
humans: 1) Cushing's Syndrome, 2) Primary aldosteronism, 3) adrenocortical
enzymatic defects.
Cushing's Syndrome is due to the prolonged exposure to excessive levels of
cortisol, the principal glucocorticoid of the human adrenal cortex. This disease
1

2
can arise from endogenous glucocorticoid excess associated with tumors of the
adrenal gland or the pituitary gland. The long-term exogenous administration of
synthetic glucocorticoids used clinically to suppress inflammation and immunity in
the treatment of diseases such as vasculitis, arthritis, skin diseases, malignancy,
primary nephrotic syndrome, secondary glomerulonephritis and transplantation can
also lead to Cushing's Syndrome ( 1 1). Since the introduction of synthetic
adrenocortical steroids as therapy for these various diseases, hypertension has
become the most frequent complication of long-term exposure to steroid therapy
( 12-14). Whatever the anatomic cause or the source, high blood pressure is the
rule in these patients. However, in Cushing's Syndrome patients there is a higher
incidence of hypertension with the endogenous occurring disease (80%) than the
long-term exogenous synthetic glucocorticoid administration (20%) (15, 16). The
explanation for this observation may be due to the low or absent mineralocorticoid
activity of synthetic glucocorticoids. Cushing's Syndrome is the cause of
hypertension in one out of 300 hypertensives ( 1 1). This is a very aggressive
disease with a 50% 5-year mortality rate if untreated ( 17). Even with present
therapy, the mortality rate is still four times that of the general population ( 18).
Thus, a new and more effective therapy is needed in the treatment of Cushing's
Syndrome.
The second disorder, primary aldosteronism, is due to the excessive
production of aldosterone independent of the renin-angiotensin system, the main
regulator of aldosterone production. Primary aldosteronism is the most common
form of endocrine hypertension occurring in patients, mostly women, between the

3
ages of 30 and 50 years. The syndrome of primary aldosteronism has been
classified in four types:
1.

Aldosterone producing adenoma (APA)

2.

Adrenocorticol hyperplasia
-idiopathatic hyperaldosteronism (IHA)
-dexamethasone suppressible hyper-aldosteronism (DSH)
-primary adrenal hyperplasia (PAH)

3.

Adrenocortical carcinoma

4.

Ectopic aldosterone-producing tumors

The most common type of primary aldosteronism is unilateral aldosterone
producing adenoma (APA) or Conn's Syndrome which accounts for 65% of
primary aldosteronism (1). APA is characterized by increased aldosterone
production from a unilateral adenoma and rarely is it bilateral. There is
suppression of the renin-angiotensin system (RAS) and urinary potassium wasting
which results in hypokalemia. APA is the second most common cause of curable
hypertension achieved through the surgical removal of the adrenal. On the other
hand, the hypertension in the other three types of primary aldosteronism are not
cured by adrenalectomy. The most common subtype of bilateral adrenocortical
hyperplasia, idiopathic hyperaldosteronism (IHA) which accounts for 34% of the
cases ( 19), unlike APA, the lHA occurs mostly as bilateral hyperplasia. The
hypertension in 85% of these patients fails to improve with adrenalectomy which
recurs within 1 to 2 weeks after surgery (19,20). Recognizing the type of primary
aldosteronism is critical in the treatment of these patients as some can be cured
partially or completely from hypertension by adrenalectomy while others cannot.

4

Therefore, other non-surgical therapeutic measures such as the use of aldosterone
antagonists like spironolactone are employed.
Adrenocortical enzymatic disorder or congenital adrenal hyperplasia (CAH)
syndrome is inherited in an autosomal recessive fashion and is characterized by
three separate enzymatic defects in cortisol biosynthesis. The deficient enzymes in
CAH, their frequency and the induction of hypertension are as follows:
Adrenocortical Enzymatic Disorders
Enzyme Deficiency

Frequency

Induction of
Hypertension

21 hydroxylase

90%

No

11S hydroxylase

8%

Yes

17 a hydroxylase

1%

Yes

The 1 1S hydroxylase and 17a hydroxylase deficiency lead to hypertension.
The 1 1S-hydroxylation deficiency is characterized by accumulation of steroids
proximal to the block such as 1 1-deoxycorticosterone (DOC) and a reduction in
1 1-hydroxylated steroids such as cortisol, distal to the defect. 17-hydroxylase
deficiency also increases the level of steroids proximal to the block and reduce
production of cortisol distally, resulting in increased secretion of ACTH. High
levels of ACTH induces the excess production of intermediate steroids including
the mineralocorticoids, DOC, 18-hydroxyl DOC and 19-nor-DOC which contribute
to the development of hypertension (1).
Adrenocortical steroids have been implicated in several models of
experimental hypertension (21) and also in human essential hypertension,

5
particularly, in low renin essential hypertension ( 19). Essential hypertension
simply means the cause(s) of the hypertension is unknown. It has been
hypothesized that in essential hypertension excess production of adrenocortical
steroids cause volume expansion (thus, suppression of renin production) which
may contribute to the development of hypertension (22). However, several studies
have shown increased (23,24) or decreased blood volume (25) in essential
hypertensive subjects. Some of these patients exhibit antihypertensive response to
adrenal inhibitors (26-28), mineralocorticoid antagonists (22,29) and
adrenalectomy (30). The potent mineralocorticoid 19-nor-DOC has been detected
in high amounts in the urine of some patients with essential hypertension (31,32).
Furthermore, other studies have shown increased adrenal activity in several
models of hypertension (33,35). However, direct adrenocortical involvement
remains to be proven. Thus, to investigate the causes and mechanisms involved in
the pathogenesis of human hypertension, different experimental models are
studied. There are several models of experimental hypertension:
1.

Mechanically-induced hypertension such as renovascular
hypertension.

2.

Genetic models of experimental hypertension.

3.

Surgical manipulations such as adrenal regeneration hypertension.

4.

Chemically induced hypertension such as steroid-induced
hypertension which is the focus of this work.

1.

Renovascular Hypertension
Goldblatt and his associates showed in 1934 that constriction of the renal

artery in dogs produced and sustained hypertension (36). Therefore, this model of

6
experimental hypertension is also known as Goldblatt hypertension. Since then it
has been shown in rats, sheep and rabbits (37,38,39). In

this

model, the renin

angiotensin system (RAS) has been known to play a major role in regulating the
blood pressure (40,41). Renin, produced by cells in the juxtaglomerular apparatus
in the kidney (due to decreased pressure in renal artery) converts angiotensinogen
produced by the liver to angiotensin I. Angiotensin I is converted to angiotensin
II by angiotensin converting enzyme (ACE) which is produced in the lungs. Ang
II is not only a potent vasoconstricting agent but also stimulates aldosterone
production from the adrenal cortex. There are two different models of Goldblatt
hypertension. The first model is known as the two kidney-one clip (2KlC) which
involves constricting the renal artery while the contralateral kidney is intact. The
second model, is the one kidney-one clip ( lK1C) in which one kidney is clipped
and the contralateral kidney is removed. The mechanisms involved in increasing
the blood pressure are different in these two models. The renin-angiotensin
system (RAS) is believed to be responsible for the development of hypertension in
the 2K1C model and not in the 1K1C model. This conclusion is based on the
observation that plasma renin activity (PRA) is elevated during the pathogenesis
of 2K1C hypertension (37,42,43). In addition, blocking the RAS with either All
antagonists or ACE inhibitors reverse increased blood pressure in 2K1C animals
(43-45). However, sodium balance in 2K1C animals has been reported to be
normal (42,46), decreased (47) or transiently increased (48,49). Unlike the 2K1C
model, the 1K1C model is not dependent on the RAS. Ang II antagonists and
ACE inhibitors have no effect or are less effective in reversing 1KIC hypertension
(43,44,50,51) and studies show a positive sodium balance. On the other hand, it
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has been suggested that the different mechanisms reported for the 2KlC and
lKlC models may be due to the fact that several studies fail to consider the
circadian rhythm for renin and aldosterone secretion, the severity of the renal
artery constriction and species differences (21).
The role of the adrenal cortex in renovascular hypertension has been
investigated.

It

has been reported that bilateral adrenalectomy reduces renal

hypertension unless there is hormone therapy (52) or saline is given (53). In
contrast, adrenalectomy lowered the BP of renal hypertensive rat to normal levels
even when they were maintained on saline (54). The administration of
prednisolone, a glucocorticoid agonist, restored the blood pressure to hypertensive
levels in adrenalectomized rats with renovascular hypertension (59). However,
glucocorticoid replacement failed to increase pressure in adrenalectomized dog
with renovascular hypertension (56). In adrenalectomized sheep given
glucocorticoid and mineralocorticoid, lKlC hypertension persisted for two days
after withdrawal of steroid (57) suggesting that the adrenal might not be that
essential in renal hypertension. Another study showed that lKlC
adrenalectomized dogs maintained on basal cortisone and l l-deoxycorticosterone
(DOC) still developed hypertension (58). Since hypersecretion of these
adrenocortical steroid hormones was not possible, it was concluded that the role of
the adrenal was not essential for the development of lKlC hypertension. De
Jong and his colleagues (59) compared renin-induced and 2KlC hypertension in
intact and adrenalectomized rat given saline. They reported that renal
hypertension developed in both intact and adrenalectomized 2KlC models.
Renin-induced hypertension developed in intact rats but not in adrenalectomized
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rats. However, high doses of renin were able to produce hypertension in
adrenalectomized rats without steroid replacement. They concluded from these
results that the adrenal is not essential for renin or renal hypertension (59).
Watkins and associates (58) also reached a similar conclusion using 1K1C
hypertensive dogs. On the other hand, a more significant role of the adrenal
gland has been suggested by Ribeiro and Krakoff (60) and other researchers (6163). Before the infusion of saralasin, the blood pressure of 1K1C rats and
adrenalectomized 1K1C was 174 mmHg and 142 mmHg, respectively, a difference
of 32 mm. This difference became 68 mmHg after saralasin infusion due to a
decrease in BP of the adrenalectomized 1K1C rats to 126 mmHg (but not in the
intact 1K1C). Since no decrease in the BP was observed in the intact 1K1C rats
with saralasin infusion, they contributed to the reduction in BP in the
adrenalectomized rats to the lack of adrenals. Aldosterone level is increased
throughout the development of 2K1C hypertension and only in the early stages of
1K1C hypertension (21). The involvement of glucocorticoids in the pathogenesis
of renovascular hypertension is sketchy but so far studies show increased levels
(64) while others observed no change (65). Thus, all these studies seem to suggest
that the adrenal gland serves a prominent but secondary role in the pathogenesis
of renovascular hypertension.
2.

Genetic Forms of Experimental Hypertension
Experimentally, there are different types of the genetic model.
Dahl and Rapp Salt-Sensitive Rats
Dahl and co-workers selectively bred Sprague-Dawley rats based on their

blood pressure response to high salt intake (66). Two strains were developed,
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namely, susceptible (S) and resistant (R). The S rats developed hypertension
rapidly on a high salt diet whereas the resistant rats did not. Rapp and Dahl have
suggested the difference between S and R rats is due to a gene or genes
controlling adrenocorticosteroids biosynthesis (67). Rapp and Dahl (68) used Fl
and F2 generations of S x R cross to show that the relative activity of steroid 18hydroxylase and 1 1-B hydroxylase (which catalyses 18- and 19-hydroxylation of
DOC) was being controlled by a single Mendelian gene with two alleles inherited
in a codominant fashion. The involvement of these steroids have been
investigated. It has been shown that R rats became hypertensive when connected
to S rats on a high-salt diet (69). Blood taken from S rats reduced the excretion
of sodium of isolated kidney from normotensive Sprague-Dawley rats (70).
Adrenalectomy prevents the development of hypertension in S rats (71). The
adrenal cortex in S rats show increased secretion in mineralocorticoids such as 18hydroxy-DOC (72), 19-nor-DOC (73,74). Also, Gomez-Sanchez reported high
levels of corticosterone in the urine of S rats than R rats (73). This finding
contradicts the observation of Rapp and Dahl (67) that blood levels of
corticosterone and the

in vitro

biosynthesis is lower in S rats than R rats. These

contradictory results have been explained by the difference in the level of 1 1-B
hydroxysteroid dehydrogenase, the enzyme that catalyses the metabolism of
corticosterone to l l-dehydrocorticosterone (75). The level of this enzyme has
been found to be higher in the S rats than the R rats.
Aside from increased mineralocorticoid secretion causing hypertension in
the S rats, sex and age also play a role. The development of hypertension in
female S rats with high salt intake is slower (67) which is contrary to reports that
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female rats have higher 18-hydroxy-DOC and 19-nor-DOC than males (73).
Therefore, the degree of response to salt by the S strain depends on factors such
as age, sex, duration and the amount of dietary salt intake (H).
Okamoto/Aoki Spontaneously Hypertensive Rats (SHR)
This is a strain of rats which develop hypertension spontaneously as they
grow. Okamoto and Aoki reported on this strain in 1963 (76). The most
interesting aspect of this strain is the possibility that SHR may be the animal
model for essential hypertension in humans. Extensive studies by Aoki (77)
proved how critical the adrenals are in the development of hypertension in the
SHR. When young prehypertensive SHR rats (less than 8 weeks old) are
adrenalectomized, thyroidectomized or hypophysectomized, the development of
hypertension is prevented (77). Even bilateral adrenalectomy in SHR with
established hypertension normalized the blood pressure, however, unilateral
adrenalectomy failed to reduce the hypertension. This is consistent in human
studies where adrenalectomy reduces blood pressure and patients with untreated
Addison's diseases have hypotension (21). Aoki and colleagues observed that the
adrenocortical zones were hypertrophied in the SHR (78). Thus, the adrenal
gland is critical in the hypertension of the SHR.
However, other researchers do not agree totally with a critical role for the
adrenal cortex in the development of hypertension in the SHR (79). Though
adrenalectomy reduces the blood pressure rise, eventually hypertension was
developed in the SHR due to the possible regeneration of accessory
adrenocortical tissue (79,80). The role played by adrenocortical steroids have also
been studied and the results are inconsistent. Several studies have shown the
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involvement of glucocorticoids. Adrenalectomized prehypertensive SHR rats with
glucocorticoid replacement restored hypertension while others have shown
aldosterone replacement to be more important (for review see 81).
Corticosterone levels at the time of significant blood pressure increase have been
observed to be higher in the SHR than control rats (82), lower in the SHR (83),
or unchanged (84). Recently, Hashimoto et al. (85) demonstrated the importance
of the pituitary-adrenal axis indicating a more important role for glucocorticoid
involvement. There has been a report of increased plasma aldosterone levels in
SHR neonates (86). In addition, high levels of the potent mineralocorticoid 19nor-DOC is found in the urine of SHR rats (87). The variability in the results of
adrenocortical function in hypertension in the SHR may be due to differences in
numerous factors. These factors are 1) age of the SHR rat at the time of study
since they develop hypertension after 8 weeks of age. Thus, it should be clear
whether prehypertensive or hypertensive rats are being studied; 2) sex of the rat
normally male SHR is used in these experiments so as to eliminate the effects of
other hormones during menstruation or pregnancy; 3) high salt or low salt diet; 4)
stress level when blood samples were taken for steroid measurements; 5) time of
day blood samples were taken as the secretion of these steroids follow a circadian
pattern; 6) strain of rats used in the experiment as controls for the SHR-whether
Sprague-Dawley, Wistar!Kyoto, and so on; 7) source of the SHR as there may be
differences in breeding in the various laboratories.
The New Zealand Genetically Hypertensive (GH) Strain of Rat
The New Zealand GH rat was developed by Smirk and Hall in 1958 (88).
These rats have significant increase in their blood pressure when they are only two
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days old which progresses as they grow. Studies of adrenocortical function in
these rats have focused on the renin-angiotensin-aldosterone system. However,
the involvement of this system has been proved otherwise. The plasma renin
activity (89) and plasma aldosterone level (90) is lower in GH rats than in control
rats. In fact, inhibition of the renin-angiotensin system does not have any effect
on the blood pressure of GH rats (91). Thus, the contention is that the renin
angiotensin-aldosterone system is not involved in the pathogenesis of hypertension
in GH rats though other mineralocorticoids other than aldosterone could play a
role. Unfortunately, there has been no reports on other mineralocorticoids or
glucocorticoids effect on this model.
The Lyon Rat Strains
Three strains of rats which are either hypertensive (LH), normotensive
(LN) or have low blood pressure (LL) have been developed by Vincent and co
workers (92). This was achieved by inbreeding of Sprague-Dawley rats identified
to have the highest, average or lowest blood pressures. Interestingly, the
hypertension that eventually develops is much less than in the SHR. Gomez
Sanchez et al. (93) have studied the role of adrenocortical steroids in the blood
pressure level in the three strains. In prehypertensive rats, which is before the age
of eight weeks, DOC levels increased significantly in the LH rats and decreased in
LL rats compared with LH rats. Hence, DOC excretion was increased in the LH
group accompanied with decreased corticosterone excretion. This observation
suggests an abnormality in the adrenal cortex such as l IB-hydroxylase deficiency.
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The Milan Hypertensive Strain (MHS) of Rat
MHS comes from the Wistar strain that were selectively bred from rats
with systolic blood pressures over 160 mmHg (94). Studies of adrenocortical
function in MH rats show a decreased plasma renin activity in prehypertensive
rats which is surprisingly followed by normal and not decreased level of
aldosterone (95,96).
The Sabra Strains of Hypertension - Prone and Hypertension-Resistant Rats
These strains were selectively bred from the Hebrew University Sabro (SB)
rats which had been uninephrectomized and saline-loaded with a blood pressure
response to DOCA treatment. This resulted in the development of two strains.
SBH that was hypertension-prone and SBN that was hypertension-resistant (97).
The abnormal function of the pituitary-adrenal axis may be involved in this form
of experimental hypertension as SBH rats have higher basal corticosterone levels
which correlates with higher ACTH levels than in the SBN rats (64).
3.

Exnerimental Hypertension Through Surgery - Adrenal Regeneration
Hypertension (ARH)
It was demonstrated by Skelton that uninephrectomized adrenal-enucleated

rats maintained on 1 % saline developed hypertension (98). An intact adrenal
gland or corticosterone administration prevented ARH but an intact pituitary
gland was necessary for the development of hypertension (99). Plasma levels of
ACTH are increased after adrenal enucleation ( 100, 101). The regenerating
adrenal gland may be secreting abnormal hormone or secreting an imbalance of
normal hormone resulting in hypertension. In fact, it has been shown that
regenerating adrenals secrete less corticosterone in response to stress ( 102) or to
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ACTH ( 103). Not only do these glands secrete lower levels of corticosterone but
also aldosterone ( 103-105). Further investigation into steroid synthesis of the
regenerating adrenal cortex revealed a reduced ability to convert progesterone to
corticosterone resulting in the accumulation of DOC which induces hypertension
( 106). This observation suggests an impairment in l IB-hydroxylase enzyme in rats
with ARH.
In contrast, other investigators have reported increased levels of 18hydroxy-DOC and not DOC ( 107-109) whilst Rapp found a decrease in the levels
of both corticosterone and 18-hydroxy-DOC ( 1 10). The inconsistency in results is
due to the difference in age of rats after adrenal regeneration and in experimental
protocol. High levels of the potent mineralocorticoid 19-nor DOC has been
detected in the urine of rats with ARH ( 1 1 1).
4.

Experimental Hypertension Through Chemical Intervention - Steroid
Induced Hypertension
Adrenocortical steroid hormones as discussed previously play a very

important role in blood pressure control. Adrenocortical hormones are broadly
classified into two major categories, namely, glucocorticoids and
mineralocorticoids. Steroid hormones known as glucocorticoids tend to be
ubiquitous affecting inflammation, immunity and intermediate metabolism.
Mineralocorticoids are vital in electrolyte balance.
Mechanism of Action of Steroid Hormones
Steroid hormones exert their biological effects by passing through the
plasma membrane and binding to specific intracellular receptors in the target
tissues. When hormone binds to the receptor, the receptor gets activated and the
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hormone-receptor complex gets translocated into the nucleus. In the nucleus, the
occupied receptor binds to specific DNA sequences which results in the regulation
of transcription of those genes in the target tissues. Steroid hormones may cause
the induction or the repression of gene transcription ( 1 12). If induction of
transcription occurs, mRNA produced is translated to proteins in the cytoplasm
resulting in de novo synthesis of proteins (translation). Steroid hormones may also
have non-genomic actions as some effects of these steroids are too fast with short
duration to be explained by a genomic mechanism ( 1 13).
The Physiological Effects of Glucocorticoids
Cortisol is essential for life as human beings cannot survive without it.
Total adrenalectomy without glucocorticoid replacement will result in death
eventually (1 14). This hormone is ubiquitous affecting cardiovascular function,
immune response, metabolism, muscle formation, behavior and almost all tissues.
Basal levels of glucocorticoids, maintained by ACTH through negative feedback
regulation modulate a variety of processes in the resting state. Most of the
glucocorticoid effects in the resting state is termed permissive because they
permit other hormones and factors to accomplish their function. Glucocorticoids
increase the level of glucose by protein catabolism. It increases total body fat at
the expense of protein.
They enhance water diuresis by preserving the rate of glomerular filtration.
They increase vascular responsiveness and modulate central nervous system
function. In addition, glucocorticoid hormones decrease lymphocytes, basophils
and eosinophils while increasing neutrophils. Thus, these hormones have effect on
immune response, CNS and renal function.
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However, high levels of cortisol in response to stress may inhibit protein
matrix formation leading to osteoporosis, and increased production of gastric acid
which increases the formation of peptic ulcers. The pharmacological effects of
glucocorticoids refer to their anti-inflammatory and anti-allergic actions.
Glucocorticoids reduce inflammation by decreasing vascular permeability,
stabilizing lysosomal membrane, inhibiting kinin production, migration and swelling
of cells. The anti-allergic effects of cortisol is due to the inhibition of antibody
production through lympholysis and histamine release. Therefore the excess
production or administration of glucocorticoids results in a series of
pathophysiological effects, the most dominant effect being hypertension.

Since

the introduction of the synthetic glucocorticoids in clinical use for a variety of
disorders, hypertension has been observed as a major complication of long-term
steroid therapy. It has been demonstrated that cortisol infusion increases blood
pressure in humans (11) and hypertension is a common complication in patients
with Cushing's Syndrome

(2). In addition, short-term administration of ACfH to

normal and hypertensive subjects raised their blood pressure, but not in patients
with Addison's disease ( 1 15) indicating an important role of cortisol production in
hypertension. The synthetic glucocorticoid agonist prednisone when given to
postrenal transplant patients has a direct correlation between the level of arterial
pressure and the dose ( 1 16). The hypertensive effects of synthetic glucocorticoids
tend to be species specific. Dexamethasone administration induces hypertension
in rats (5, 1 17, 1 18) but not in sheep ( 1 19). However, ACfH infusion quickly
raised the blood pressure in sheep while cortisol, aldosterone or
deoxycorticosterone (DOC) had far less hypertensive effect (11).
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The Characteristics of Glucocorticoid-Induced Hxpertension
Glucocorticoid-induced hypertension is not affected by a reduction in renal
mass or dietary salt intake (120, 121). Rats fed a high or low salt diet develop
glucocorticoid hypertension ( 120). Dietary salt restrictions failed to abolish
glucocorticoid-induced hypertension and only lowered blood pressure slightly
( 121). This model of experimental hypertension occurs without hypokalemia or
suppression of the renin-angiotensin system. In fact, studies show that
glucocorticoids increase angiotensinogen secretion ( 122) as well as the renin
concentration (123).
Glucocorticoid treatment is associated with increased water consumption,
urinary output and sodium excretion

(natriuresis) resulting in a negative

sodium balance (5, 125). However, hematocrits of rats with glucocorticoid excess
hypertension are lower, suggesting an increase in plasma volume ( 124). One of
the hallmarks of experimental glucocorticoid-induced hypertension using
dexamethasone is a great reduction in body weight caused mainly by skeletal
muscle catabolism. Glucocorticoid-induced hypertension is also characterized by a
rapid increase in blood pressure which is observed within a week of steroid
administration (5,125).
Though excess glucocorticoids are known to increase arterial blood
pressure, the biochemical mechanisms by which they induce and maintain
hypertension are unclear. Several factors have been implicated in the actual
pathogenic mechanisms such as enhanced response of vascular smooth muscle to
pressor agents (126), activation of the renin-angiotensin system (127), fluid
movement from intracellular to extracellular compartments (121) among others.
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Possible Mechanisms of Glucocorticoid-Induced H)lJertension
1.

Electrolyte Balance

Glucocorticoid-induced hypertension does not require high dietary salt
intake (unlike mineralocorticoid-induced hypertension) (120). However, other
studies using the naturally occurring glucocorticoid cortisol or corticosterone, have
shown that dietary salt restriction reduced the rise in blood pressure although it
did not totally prevent it (128). This observation has been explained by the fact
that cortisol and corticosterone possess both glucocorticoid and mineralocorticoid
actions and may raise blood pressure by both mechanisms. Free cortisol has 1 %
to 2% the affinity of aldosterone for mineralocorticoid receptors in the kidney
(129). Thus, if cortisol exceeds the binding capacity of binding globulins and
glucocorticoid receptors, the free cortisol could contribute to mineralocorticoid
activity. This has been observed as a possible occurrence in some patients with
Cushing's disease (1). On the other hand, synthetic glucocorticoid agonists such as
dexamethasone (5,130) and RU 26988 (131) have virtually no mineralocorticoid
activity and yet cause experimental hypertension. In fact, dexamethasone has
antimineralocorticoid effect in the rat ( 132) but still raises blood pressure
indicating that salt intake and thus, electrolyte balance is not essential for
glucocorticoid hypertension and therefore other mechanisms may be involved.
2.

Fluid Compartmentalization

Administration of glucocorticoids causes fluid shift from the intracellular to
the extracellular compartments thereby increasing the extracellular fluid volume
( 121). Glucocorticoids activate cell membrane Na + K+ ATPase, an enzyme which
promotes the exchange of sodium ions from the cell for potassium ions outside the
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cell. The extrusion of Na + from the cell is followed by water increasing the
volume of the extracellular compartment. The Na+/K+ APase activity is
increased in erythrocytes of patients with Cushing's Syndrome (133) and those
treated with ACfH ( 134). Glucocorticoids increase NA+/K+ ATPase in human
erythrocytes (135) and in myocardial tissue of SHR and normotensive rats (136).
Thus, in spite of a negative salt balance, there is a shift of water from inside to the
outside of the cell resulting in hypervolemia. The immediate effect of prolonged
hypervolemia will be increased cardiac output which may ultimately result in
increased peripheral resistance through autoregulatory mechanisms and hence
hypertension. However, it has been observed that the increase in extracellular
fluid volume does not correlate well with the increase in arterial pressure (137).
Since glucocorticoid-induced hypertension cannot be fully accounted for by
hypervolemia, other mechanisms may be contributing.
3.

Renin-Angiotensin System

Inhibition of the renin-angiotensin system (RAS) in glucocorticoid-induced
hypertension reduces the high blood pressure (138,139). This indicates the role of
the RAS in this model of hypertension. Glucocorticoids stimulate and maintain
the action of the RAS in contrast to suppression of this system by the actions of
mineralocorticoid. The formation of the renin substrate angiotensinogen is
induced in the liver by glucocorticoids (140). The level of plasma angiotensinogen
is raised in patients with Cushing's Syndrome (122) and in experimental models of
glucocorticoid hypertension ( 1 17). Angiotensinogen is catalyzed by renin to form
angiotensin I (AI) which is then converted to angiotensin II (All), by the
converting enzyme produced by the lungs. Glucocorticoids maintain this lung
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converting enzyme as adrenalectomy reduces the level of the enzyme appreciably
which is restored by dexamethasone but not mineralocorticoid replacement (141).
In all, the angiotensin formation has been reported to be increased by about 40%
due to glucocorticoid actions ( 123). On the other hand, others have observed that
adrenalectomy had no significant effect on the

in vivo

conversion of AI to All

( 142). Though in the normal subjects cortisol excess reduces plasma renin
concentration due to increased plasma volume, the plasma renin activity (PRA)
may be low, normal or elevated in Cushing's Syndrome patients ( 143, 144).
Administration of the All antagonist saralasin or the converting enzyme inhibitor,
captopril, decreases pressure in experimental glucocorticoid hypertension
( 1 1 7,138, 139). When captopril is administered simultaneously with excess
glucocorticoids, hypertension is delayed but not fully prevented (145). Inhibiting
the RAS in patients with Cushing's Syndrome has given inconsistent results ( 146148). Patients with high PRA showed markedly reduced arterial pressure,
however, the pressure is still higher than normotensives (148). Therefore, the
RAS may participate in glucocorticoid-induced hypertension but it does not
entirely account for the elevation in arterial pressure observed.
4.

Vascular Smooth Muscle Reactivity

Glucocorticoids may induce hypertension by enhancing the response of
vascular smooth muscle (VSM) to pressor agents such as catecholamine and other
adrenergic agonists (114). It has been shown in normal human subjects ( 149) and
several animal species (150-152) that glucocorticoids increase vascular
responsiveness to alpha-adrenergic amines. On the other hand, lack of cortisol
diminishes cardiovascular sensitivity to pressor substances leading to hypotension

21
( 1 14). Patients with adrenal insufficiency are hypotensive and resistant to pressor
agents unless treated with adrenal steroid hormones ( 153). In experimental
animals with bilateral adrenalectomy, VSM is insensitive to vasoconstrictors unless
pretreated with glucocortiocids ( 154). This led to the hypothesis that
cardiovascular collapse in adrenal crises may be partially due to insensitivity of
VSM to vasoconstrictor agents ( 155).
The type of glucocorticoid agonist and dose administered are important
factors in potentiating the pressor response of VSM to a particular vasoactive
substance. Cortisol administration to normal subjects increases the pressor
response to phenylpherine but not to AIl ( 149). Dexamethasone given in
experimental glucocorticoid hypertension enhances VSM response to NE (150)
but when methylprednisolone is given, the VSM pressor response to NE or AIl
was not enhanced ( 1 17, 139). However, selective glucocorticoid deficiency reduces
pressor response to NE and AIl ( 142). The antagonism of endogenous
glucocorticoids by RU 486 result in reduced pressor response to angiotensin II
(Ail) and norepinephrine (NE (125).
Thus, the normal endogenous glucocorticoid concentration (within
physiological range) may be required for normal vascular responsiveness but
whether excess glucocorticoids corresponds to a direct increase in responsiveness
to pressor agents leading to hypertension needs to be proven.
Specific glucocorticoid receptors are found in brain (156), cardiac and
vascular tissues ( 157) of animals and the arterial smooth muscle cells in humans
( 158). However, glucocorticoids may have different actions in different tissues as
proteins induced by glucocorticoids are tissue-specific (159). It has been
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postulated that glucocorticoids may increase VSM responsiveness to epinephrine
(E) by inhibiting the enzyme catechol-o-methyl transferase (COMT) thereby
preventing the breakdown of E ( 160). The reason for this postulation stems from
the observation that cortisol potentiates the pressor effect of E and not NE in
experimental animals ( 160). Other possible explanation for glucocorticoid induced
VSM responsiveness include increased Na + K+ pump activity and structural
changes at the vascular wall ( 1 14). Although increased pressor responses are
observed in VSM in

vitro

these local effects are not seen in

vivo

after

glucocorticoid treatment. In humans, it has been reported that administering
glucocorticoids increase pressor response to NE and E ( 152) whereas others
observed no effect ( 1 17, 161). These inconsistencies between in vitro and in

vivo

glucocorticoid-induced vascular response may be explained by the compensatory
cardiovascular reflexes which might occur in

vivo.

Thus, the literature on VSM

reactivity as a possible mechanism for glucocorticoid hypertension is inconclusive.
5.

Renal Function

The role of adrenocorticosteroid hormones in the maintenance of normal
renal function is well established ( 162). In adrenal insufficiency (Addison's
diseases) both glomerular filtrate rate (GFR) and renal blood flow (RBF) are very
low ( 1 1). Glucocorticoids increase GFR while total RBF remains constant thereby
increasing the filtration fraction (GFRJRBF) ( 163). This may explain why there is
an exaggerated natriuresis in patients with Cushing's Syndrome ( 164, 165) and, also
in normal individuals fed a high dietary salt intake and given cortisone ( 165).
Unfortunately, how these changes in renal function contribute to glucocorticoid
hypertension are not known.
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6.

Prostaglandins

The production of the vasodilator prostaglandins by white blood cells is
inhibited by glucocorticoid action (150). It has been shown in vitro that
glucocorticoids affect the biosynthesis of prostaglandins by inhibiting the release of
arachidonic acid from phospholipids ( 166). They induce a protein, macrocortin,
which inhibits phospholipase A2, the enzyme that releases arachidonic acid from
phospholipids. In arterial tissue, glucocorticoids directly inhibit the synthesis of
prostacyclin ( 167). Prostaglandin E2 (PGEz) excretion from the kidneys is also
reduced ( 150). Thus, glucocorticoids might raise blood pressure through the
inhibition of phospholipase A2 leading to a reduction in the activity of vasodilator
protanoids. Dexamethasone-induced hypertension was prevented by the
administration of a fish-oil diet which increases the formation of vasodilator
prostaglandins (168). On the other hand,

in vivo

studies show that glucocorticoids

have little effect on prostaglandin formation (169). In fact, glucocorticoids may
increase the synthesis of some prostanoids by renal tissues (167, 170). In addition,
glucocorticoids might increase synthesis of prostaglandins through its lipolytic
effect on triglycerides which increases arachidonic acid (170). Therefore,
prostaglandin deficiency as mechanism of glucocorticoid-induced hypertension is
not conclusive.
7.

Other Cardiovascular Effects of Glucocorticoids

Glucocorticoids may also control the sympathoadrenal function by
stimulating the production of the enzyme, phenylethanolamine-N
methyltransferase (PMNT) which catalyzes the conversion of NE to E. Inhibition
of PMNT ( 171) or blockade of sympathetic ganglion ( 1 17) reduces glucocorticoid-
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induced hypertension. Also, cardiac and lung beta receptors are increased by
glucocorticoid treatment (172). However, there is no evidence that there is an
increase in catecholamine production or sympathetic nervous system activity by
glucocorticoid treatment.
Actions of Mineralocorticoids
The main action of mineralocorticoids on blood pressure is due to their
effects is on salt and water balance. They increase sodium retention which raises
the extracellular fluid volume and if prolonged, may increase the cardiac output
leading to a high total peripheral resistance via Guyton's model of autoregulation
(173). The actions of mineralocorticoids stimulate sodium transport from
secretory cells such as the renal tubular cells, salivary gland, sweat glands and
gastrointestinal tract. Increased sodium transport from the renal tubular cells into
the extracellular fluid creates a negative intraluminal pH and subsequently
potassium and hydrogen ions are excreted (3). The major mineralocorticoid is
aldosterone.
Aldosterone secretion is regulated by the renin-angiotensin system and
increases when extracellular volume decreases. Renin, produced by the
juxtamedullary apparatus in the kidney when renal artery pressure is low, converts
the substrate angiotensiongen produced by the liver to angiotensin I (AI). A
converting enzyme synthesized in the lungs catalyzes the conversion of AI to All.
All stimulates the synthesis of aldosterone from the zona glomerulosa of the
adrenal cortex. The exogenous administrtion of aldosterone induces hypertension
in experimental animals (9, 10), as well as in humans (8). Primary aldosterone
which can be due to adrenal adenoma (APA), adrenal carcinoma or bilateral
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hyperplasia resulting in over production of aldosterone, is associated with
hypertension (3). Another mineralocorticoid well studied in mineralocorticoid
induced hypertension is deoxycorticosterone (DOC). In congenital adrenal
hyperplasia, 1 18 and 17cr-hydroxylase deficiency resulting in excess DOC
production is also associated with hypertension (3). Furthermore, administering
DOC to rats ( 174), pigs (179), dogs (176) and humans ( 177) caused a blood
pressure increase. Unlike aldosterone, DOC is regulated by the ACTH levels and
has been shown that in Cushing's Syndrome patients, the excessive production of
ACTH results not only in hypersecretion of cortisol but also of DOC (1).
Besides aldosterone and DOC, other mineralocorticoids have been shown
to induce hypertension (1). A potent mineralocorticoid, 19-nor DOC, induces
hypertension in rats ( 178) and is suspected of playing a major role in hypertension
developed by SHR (87).
Characteristics of Mineralocorticoid Hypertension
1.

Unlike glucocorticoid-induced hypertension, mineralocorticoid-

induced hypertension is dependent on dietary salt intake and reduced renal mass
(124). Thus, a well-established model of mineralocorticoid-induced hypertension
in rat is DOC administration combined with high salt intake and reduced renal
mass.
2.

Mineralocorticoid-induced hypertension is characterized by increased

sodium retention resulting in hypernatremia followed by increased water retention.
3.

Reduced hematocrit indicating increased plasma fluid.

4.

Increased fluid intake (Polydipsia).

5.

Increased body weight.
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6.

Increased potassium and hydrogen excretion resulting in

hypokalemia and alkalosis, respectively.
7.

Increase in blood pressure with a slow onset.

8.

One of the most consistent biochemical effects of excess

mineralocorticoid is suppression of the renin-angiotensin system via a negative
feedback mechanism.
Whereas, mineralocorticoids increase renal sodium and fluid reabsorption
resulting in increased extracellular fluid volume and gain in body weight, excess
glucocorticoids is associated with a negative sodium balance and great reduction in
body weight ( 124). However, the end result is the same, that is, increased blood
pressure. Thus, the mechanisms employed by these two steroids in inducing
hypertension are believed to be different although the actual pathogenic
mechanisms responsible for the development and maintenance of steroid-induced
hypertension are not known.
Possible Mechanisms of Mineralocorticoid Hypertension
1.

Electrolyte Balance

The actions of mineralocorticoids on ion transport lead to increased sodium
retention and then increased extracellular fluid volume resulting in increased
cardiac output (8). The autoregulatory mechanisms set off by increased cardiac
output returns the cardiac output to a normal level but at the expense of
increased total peripheral resistance which leads to a rise in arterial pressure
( 173). Dogs treated with metyrapone ( 17) and pigs implanted with
deoxycorticosterone acetate ( 18) suggest that the elevation of blood pressure is
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associated with variable relative elevation in cardiac output and peripheral
resistance.
2.

Vascular Reactivity

Excess aldosterone causes increased sodium retention and intracellular
sodium content in tissues which may lead to increased vascular reactivity and
contributing further to blood pressure elevation. Aldosterone may stimulate
passive and sodium pump-dependent Na + transmembrane movements in vascular
smooth muscle (9). These effects are blocked in a dose-dependent fashion by
mineralocorticoid antagonists. Several studies have shown that mineralocorticoid
administration enhances vascular sensitivity to vasoactive substances such as
epinephrine and angiotensin II (179) which occurs prior to increase in peripheral
resistance ( 174). Evidence for this proposed mechanism stems from the
observation that high affinity specific binding mineralocorticoid receptors are
present in the cytosol of vascular smooth muscle cells ( 180). Though not
conclusive, this suggests the possibility of a direct effect of mineralocorticoids on
VSM. The most convincing evidence is from the result of Komel et al. ( 181).
They showed the existence in the arterial wall of an in situ molecular mechanism
for mineralocorticoids. However, there is evidence that the action of steroid
hormones on VSM is indirect (182).
3.

Central Nervous System (CNS)

It has also been postulated that since high affinity, specific binding sites for
aldosterone are found in various parts of the brain associated with blood pressure
regulation, excess mineralocorticoids might have a direct effect on the central
nervous system when they bind to these receptors (183,184).
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Intracerebroventricular infusion of low doses of aldosterone induces hypertension
in mononephrectomized saline drinking Sprague-Dawley rats and the simultaneous
infusion of prorenone, a potent and specific mineralocorticoid antagonist, blocked
the pressor effects of aldosterone ( 186). This study provides a strong evidence for
a direct hypertensinogenic effect of aldosterone in the CNS. Other studies have
shown that Jesioning the anteroventral part of the hypothalamus (AV3V) prevents
the development of mineralocorticoid-induced hypertension (179). It is thought
that mineralocorticoids may change the intracellular sodium content of these
hypothalamic cells affecting the release of agents such as vasopressin that
stimulate drinking or influence vascular responsiveness ( 179).
Another possible mechanism of aldosterone is through the release of atrial
natriuretic factor (ANF) to combat extracellular volume increase induced by
mineralocorticoid actions ( 186). The biochemical mechanisms of ANF are not
clear but it is possible some of its actions raises the blood pressure. The actions
of ANF are complex but it is believed to act as an Na+K+ ATPase inhibitor
counteracting the effects of aldosterone in the kidney (186). ANF stimulates an
increase in the CGFR and prevents renal reabsorption of sodium and water, thus,
acting as a powerful diuretic ( 187).

In addition, ANF blunts renin release and

has been shown to lower plasma renin levels in dogs ( 187). It also blocks the
synthesis and release of aldosterone (188, 189) and vasopressin (190). These
effects of ANF actions promote diuresis and natriuresis and block the production
and actions of the RAS and vasopressin and other pressor agents (187). Although
these should lower the blood pressure, there is evidence ANF may ultimately lead
to increased blood pressure (191). The natriuretic hormone not only inhibits the
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sodium pump in the kidney, but in other types of cells including those of the VSM
(192). Blaustein (193) has proposed that inhibition of Na +K+ ATPase activity
leads to increased intracellular sodium which reduces the sodium gradient thus the
Na+/Ca2+ exchange fails to operate raising the intracellular calcium ion
concentration. Calcium ions are responsible for muscle contraction and an
increase will make the VSM contract more readily. Long periods of enhanced
arteriolar contraction may lead to structural changes in the vascular walls with a
rise in arterial pressure. In addition, changes in the ionic content of smooth
muscle cells can increase contractility by enhancing their response to
vasoconstrictive agents. Haddy and associates (144) observed that pump
suppression increased blood vessel sensitivity to norepinephrine with elevation in
blood pressure. Several researchers have observed high intracellular sodium ion
concentration in various cell types from humans (193-195) and animals (196, 197)
with hypertension. Takeda and Miyamori has reported a significant increase in
the basal levels of plasma ANF in essential hypertensive subjects as compared
with age-matched normotensives (191). On the contrary, other researchers failed
to demonstrate any significant difference in plasma ANF levels between
hypertensive and normotensive groups (198-200). Thus, the role of ANF in the
pathogenesis of hypertension is inconclusive.
In summary, the pathogenic mechanisms contributing to steroid-induced
hypertension are numerous and undefined. Overall, it is likely that steroid
hormones may exert their effect by binding to their receptor (receptor-mediated
genomic actions) but also they can act through non-receptor mediated events
termed the "hypertensinogenic" action ( 1 19). These could explain the reason why
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the possible mechanisms in steroid-induced hypertension are not sufficient to
account for the rise in blood pressure observed.

RATIONALE

Since excess mineralocorticoids and glucocorticoids are known to induce
hypertension in several diseases, the therapeutic value of adrenocortical steroid
hormone antagonists in the clinical treatment of such diseases is very important.
Unfortunately, research in this area has been slow because there are no potent
and specific antiglucocorticoids or anti-mineralocorticoids available. Those
available are limited in their experimental and clinical usefulness as they often
exhibit some agonist activity (2 0 1) or cross-reactivity with other steroid hormone
receptors (201,202). Glucocorticoid antagonists may be active only in
in vivo (201)

vitro

and not

while mineralocorticoid antagonist such as spironolactone has serious

endocrinological side effects due to its high affinity for the androgen and
progesterone receptors (202). Thus, since the introduction of these steroid
hormone antagonists, the search for new and pure glucocorticoid antagonists
which are active both in

vitro

and in

vivo

and mineralocorticoid antagonists with

less endocrinological side effects has been going on. Recently, researchers at
Roussel-Uclaf have synthesized an exciting multifaceted steroid hormone
antagonist known as RU 4861 or mefiprestone which is the first known pure

1RU 486 [17-Hydroxy-l l (4 dimethyl aminophenyl-l») 17(lpropynyl)-estra-4-diene 3 one).
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glucocorticoid antagonist which is active not only in

vitro

but also

in vivo

without

any agonist effects (203). They have also synthesized a new mineralocorticoid
antagonist designated RU 267522. Scientists at Schering (West Germany) have
recently synthesized a novel antimineralocorticoid compound known as
mespirenone3.
Since these new and potent antagonists are now available, it is of great
clinical and scientific interest to study its therapeutic potential in

vivo.

Antagonists

for steroid hormones are important not only for clinical use but also as tools for
probing the molecular mechanisms of hormone action about which only little is
known. It has previously been shown in this laboratory that RU 486 successfully
prevents the hypertension induced by the long-term administration of
dexamethasone (5). Thus, the long-term in

vivo

effect of RU 486 was studied in

rats to show the significance of this drug. However, the specificity of RU 486 as
an antiglucocorticoid in preventing adrenocorticoid-induced hypertension is not
known. Thus, this study was initiated to investigate if RU 486 possesses some
mineralocorticoid agonist or antagonist properties. On the other hand, no

in vivo

studies have been done with the newly synthesized mineralocorticoid antagonists,
RU 26752 and mespirenone on steroid-induced hypertension until now. Though
in vitro

studies have shown increased affinity of these compounds for the

mineralocorticoid receptor (MR) over the clinically used antimineralocorticoid,
spironolactone, surprisingly no studies have been done to follow up the potency of

2RU 2675 (7« -propyl-3-oxo-17« -pregn-4-ene 21, 17-carbolactone).
3Mespirenone (7« -acetylthio-15 p -methylene-3-oxo-17 « -pregna-1,4-diene-21, 17 -carbolactone).
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these drugs to show if increased
with their

in vivo

in vitro

affinity for the MR is fairly correlated

pharmacological action. Therefore, for the first time,

in vivo

studies have been conducted to evaluate the antimineralocorticoid effect of RU
26752 and mespirenone in rats.
The goal of this work was to investigate the antihypertensive effect of these
novel antagonists since the most common complication of excess adrenocortical
steroid hormone production is hypertension. The specific aims were: 1) to
evaluate the specificity of RU 486 as an antiglucocorticoid by assessing its effect
on mineralocorticoid-induced hypertension; 2) to study the long-term in

vivo

effect

of the newly synthesized mineralocorticoid antagonists RU 26752 and mespirenone
on mineralocorticoid-induced hypertension in rats to establish the significance of
these compounds; 3) To assess if RU 26752 and mespirenone are specific for
mineralocorticoid-induced hypertension or if they also prevent glucocorticoid
induced hypertension in rats; 4) to elucidate whether glucocorticoid and
mineralocorticoid antagonists are effective in the treatment of the genetic model
of hypertension; namely, the spontaneously hypertensive rat (SHR). In the
literature, there are several reports implicating adrenocorticosteroid hormones in
the development and maintenance of the SHR (82,85-87). The study of the SHR
is also important because it is thought to be the closest model of experimental
hypertension to the human essential hypertension.

MATERIALS AND METHODS

Deoxycorticosterone acetate (DOCA) d-aldosterone and dexamethasone
were purchased from Sigma Chemical Co. (St. Louis, MO). Aldosterone and RU
26752 custom-made pellets were obtained from Innovative Research of America
(Toledo, OH), RU 38486 and RU 26752 (for injection, not pellets) were a gift
from Roussel-Uelaf Pharmaceutical Company (France). Mespirenone was also
donated by the Schering Chemical Company (Germany). Olive oil used as the
vehicle was of the Pompeian brand. Male Sprague-Dawley rats (CD strain)
weighing between 250-300g and six-week-old male spontaneously hypertensive rats
(SHR) were obtained from Charles River Breeding Laboratories. The rats were
housed in individual metabolic cages under environmentally controlled conditions
exposed to 12 hours of light and 12 hours of darkness. Rats were given Purina rat
chow and water ad libitum. Institutional Animal Care and Use Committee
guidelines were followed to prevent pain during surgical procedure and throughout
the experimental period.
General Methodology
Blood Pressure Measurements
Systolic blood pressure of all rats was determined by the tail-cuff method
(204). An l ITC photoelectric pulse pressure transducer (MOD 29 pulse
amplifier) (Woodland Hills, CA), a Grass polygraph (Model 7) (Quincy, MA), a
34
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Narco automatic cuff inflator and rat temperature control unit (Houston, TX)
were used. Animals were given at least 30 minutes to get accustomed to the
constraint unit before pressure recordings were made. To get reliable data,
recordings were done when animals were obviously calm as stress will increase
glucocorticoid levels which can alter the blood pressure. In addition, taking into
consideration the fact that steroid hormone release follows a circadian rhythm, it
became imperative for recordings not to be done at the peak time (that is at 4
p.m.) and also each set of recordings should be done always at the same time of
the day. Temperature around the rat tail was maintained at 30°C throughout the
recording period. The systolic blood pressure (SBP) was taken. The SBP was
taken only when the reading was stable. The SBP was considered stable when six
consecutive clear readings were the same or were within 5 mmHg of each other.
The blood pressure represent the average of at least six measurements for each
rat per week. Blood pressure measurements were done once every week during
the experimental period. Calibration of the drive amplifier on the Grass
polygraph to set the baseline was done before each set of measurements.
All rats were weighed on the same day after blood pressure measurements
had been taken. To keep stress to a minimum, rats were never weighed or
injected before blood pressure recordings were done.
Injection Regimen
Olive oil was used as the vehicle. Injections were given intramuscularly or
subcutaneously on the leg of the rats. Precaution was taken to avoid bleeding as
bleeding would have caused leakage of the solution. Injections were not given
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consecutively on the same leg so as to prevent swelling. To ensure even
concentration of the injection solution, the solutions were thoroughly stirred just
before each animal was injected.
Fluid Consumption and Urinary Output Recording
Fluid intake and urinary output of the rats were taken on two consecutive
days each week during the experimental period. Animals were transferred to
metabolic cages and had free access to Purina rat chow and water or 0.9% saline
depending on the experimental model of steroid-induced hypertension. The fluid
was in a graduated bottle so that fluid intake was easily determined. Graduated
plastic bottles were attached to the bottom of the metabolic cages to determine
urine volume. Readings were taken over a 24-hour period thus taking into
account the circadian nature of steroid hormone release and their influence on
fluid intake and urinary output.
An

average of the values on two consecutive days represent the fluid intake

and urine output of each group. Metabolic cages needed to be cleaned after each
set of collection or the connection from cage to urine collecting bottle could be
blocked with chow and fecal material thus underestimating the urine volume.
Samples of urine were frozen and later used in the determination of
sodium and potassium concentration by flame photometry.

Some values obtained

were so variable even within groups that they were not useful in drawing any
conclusions from them and therefore were not included in these studies.
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Histological Preparation of Organs
At the end of the experimental period, the rats were anesthetized with
carbon dioxide and killed by cervical dislocation. The liver, heart, kidney and
thymus were quickly removed and weighed. Heart and kidney tissues were
immediately placed in buffered formalin. Tissue sections were cut of the heart
and kidney and stained with Masson's trichrome which is a fuchsin stain. This
stain was used to identify areas of myocardial degeneration of heart tissues and
interstitial nephritis of kidney tissues. The severity of myocardial degeneration
and interstitial nephritis was indicated by the extent of fuchsinophilia.
Analysis of Data
All the data collected were analyzed statistically by the two-way analysis of
variance (ANOVA) followed by the Scheffes' test for multiple comparisons using
the STAT computer program. All graphs were done by Sigma plot.

CHAPTER 1

The Role of the Glucocorticoid Antagonist RU 486 in
Adrenocorticosteroid-Induced Hypertension
Abstract
Previously, we have shown that RU 486 successfully prevented the
hypertension induced by the long-term administration of dexamethasone to male
Sprague-Dawley rats (5). In the present study, we determined the effect of RU
486 on two other experimental models of hypertension in the rat, namely, the
deoxycorticosterone acetate (DOCA)-salt and the spontaneously hypertensive rats
(SHR). Uninephrectomized saline-drinking male Sprague-Dawley rats were
divided into 3 groups and given either 0.2 ml olive oil (control), I mg DOCA, or

I

mg DOCA+ 10 mg RU 486 dissolved in 0.2 ml olive oil every third day for a
period of three weeks. Within a week of steroid administration, there was a sharp
increase in the systolic blood pressure (SBP) in the DOCA-salt (170
DOCA + RU 486 ( 173

±

1.6) treated rats over the control rats (127

±
±

2.8) and
3.5) which

remained elevated throughout the experimental period. There was significant
difference in the water consumption and urinary output between the control and
DOCA + RU 486 treated rats. In the experiment involving the SHR, the rats
were divided into groups I, II, and III and given 0.2 ml olive oil (control), 1 mg
RU 486, and 5 mg RU 486 dissolved in 0.2 ml olive oil respectively, for 3 weeks.
38
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Instead of a decrease in the blood pressure as might be expected, surprisingly RU
486 enhanced it significantly within three weeks of drug administration. Control
and 5 mg RU 486 treated rats had SBP of 153

±

1.7, and 172

±

2.5, respectively,

during the three-week experimental period. Water intake, urinary output, body
and organ weights were comparable in all groups. It is concluded that RU 486
has no effect on DOCA-salt model of hypertension but interestingly, elevates the
hypertension in the SHR.
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Introduction
Until recently, antiglucocorticoids available were active only in
weakly active

in vivo

vitro

or

(201). A new glucocorticoid antagonist denoted RU 486 is

the first known potent antiglucocorticoid active

in vitro

as well as

in vivo

in

different target tissues (203). RU 486 given orally (205), intraperitoneally (206)
and intramuscularly (207) results in antiglucocosticoid responses. Early studies of
RU 486 treatment in patients with Cushing's Syndrome showed a partial or
complete reversal of hypokalemic alkalosis found in these patients which is due to
the mineralocorticoid activity of excess cortisol produced in these patients (208).
This has led to the speculation that RU 486 and/or some of its metabolites might
have some antimineralocorticoid activity. This speculation is valid because steroid
hormone antagonist often cross-react with other hormone receptors. RU 486 not
only binds the glucocorticoid receptor but has a strong affinity for the
progesterone receptor and to a lesser extent to the androgen receptor (209). But
in vitro

studies have shown negligible cross-binding of RU 486 with the rat renal

mineralocorticoid receptor (209). Since progesterone possesses
antimineralocorticoid activity (210), it is possible that RU 486 may have some
mineralocorticoid agonist or antagonist activities dependent on its antiprogestin
properties. In addition, RU 486 may exert its apparent antimineralocorticoid
effects via its antagonism of glucocorticoid action. Naturally occurring
glucocorticoids may potentiate the mineralocorticoid sodium retention effect by
increasing the extracellular volume and the glomerular filtration rate (GFR)
(121, 163). A glucocorticoid antagonist such as RU 486 might then show
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antimineralocorticoid activity by decreasing the ECF and GFR and thus, amount
of water and sodium delivered to the distal and collecting tubules. Therefore, RU
486 may be exhibiting anti-mineralocorticoid activity indirectly through its
antagonism of the actions of these other hormones. Studies show that depending
on the response examined, RU 486 can act both as a suboptimal or optimal
antagonist. Steroid hormone antagonists may possess partial agonist activity and
such antagonists are referred to as "suboptimal inducer" or a partial agonist
antagonist" and their action is known as "suboptimal antagonism."

An

optimal

antagonist is therefore devoid of agonist activity and it is able to antagonize
completely the effects of an optimal agonist. Some studies have reported that RU
486 exhibits no agonist activity even when administered in large doses (see 211 for
review) while others have observed mild glucocorticoid agonist activity (212).
Therefore, RU 486 may have some mineralocorticoid agonist or antagonist
properties dependent or independent of its antiglucocorticoid and antiprogestin
properties. Although

in vitro

studies have shown negligible cross-binding of RU

486 with the rat renal mineralocorticoid receptors (209), this may not correlate
well with its

in vivo

potency as the compound may be modified by its

pharmacokinetic and metabolic activities that may produce reactive metabolites
which determines its overall biological activity.
Previously, we have shown in this laboratory that RU 486 was able to
prevent the hypertension induced by long-term administration of dexamethasone
to Sprague-Dawley rats (5). However, the specificity of RU 486 in preventing
adrenocorticoid-induced hypertension is not known. For example, could RU 486
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have any agonistic or antagonistic mineralocorticoid effect in the rat? Therefore,
the specificity of RU 486 in preventing glucocorticoid-induced hypertension was
investigated by studying its effect on two other models of experimental
hypertension, namely, the DOCA-salt and the spontaneously hypertensive rats
(SHR).
Materials and Methods
Blood pressure measurements and the weights of the rats were taken on
days 0, 7, 14 and 21. For initiating DOCA-salt-induced hypertension, the Sprague
Dawley rats were right uninephrectomized under ether anesthesia. A week after
uninephrectomy, the animals were divided into three groups of eight rats each
(n= 8) and the baseline blood pressure measurements were taken. Steroid
administration was by intramuscular injections every third day for 18 days (total 7
injections). Group I (n= 8) received 0.2 ml olive oil/300 g, Group II (n= 8)
received 1 mg DOCN300 g and Group III (n= 8) received 1 mg DOCA + 10 mg
RU 486/300 g dissolved in 0.2 ml olive oil. The SHR animals were also divided
into 3 groups and blood pressure taken on days 0, 7, 14 and 21. Injections were
given intramuscularly every third day for 18 days as above. Group I (n= 8) was
given 0.2 ml olive oil/ISO g, Group II (n= 8) received 1 mg RU 486/150 g and
Group III (n= 8) received 5 mg RU 486/150 g dissolved in 0.2 ml olive oil.
Fluid consumption and urinary output were recorded on two consecutive
days each week (total of six recordings). At the end of the experimental period,
animals were anesthetized with carbon dioxide and sacrificed by cervical
dislocation. The heart, kidney, thymus and liver were quickly removed and
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weighed. The heart and kidney tissues were histologically prepared for
morphological examination. All data collected were analyzed by the two-way
analysis of variance followed by the Scheffe's test for multiple comparisons.
Results
Results presented in Figure 1 demonstrate the effect of RU 486 on
dexamethasone-induced hypertension (Am. J. PhysioJ. 256:E683) which serves as
an introduction to this work. Results presented in Figure 2 and Table 1 show that
within a week of steroid administration, there was a sharp increase in the blood
pressure in the DOCA-salt treated rats (170

±

2.8) over the control rats (127

±

3.5) which remained elevated over the three weeks of experiment. The
simultaneous administration of DOCA + RU 486 (173

±

3.1) was unable to

prevent or potentiate the hypertension induced by DOCA-salt treatment.
No significant difference in the weights among the groups was noted during
this three-week period (Table II). Data shown in Table II demonstrate a
significant increase in saline consumption in the rats injected with DOCA + RU
486 (66

±

3.5) as compared to control rats (41.50

±

2.0). This was followed by a

correspondingly higher urine output in the former rats (23

±

3.2). There was no

significant difference observed in the weight of kidney and heart among the three
groups.

When male SHR were given RU 486 (comparable to those given to DOCA
+ RU 486 on weight basis) for 3 weeks by injection (Fig. 3 and Table III) instead
of decreasing the blood pressure, RU 486 significantly increased it ( 172
over the controls (125

±

±

2.5)

2.1). However, RU 486 had no significant effect on body
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weight, water intake, urinary output and organ weight of the

SHR

animals (Table

IV).
Morphological examination of histologically prepared sections of the heart
and kidney showed no abnormalities, that is, fuchsinophila of the myocardium and
renal tissue were considered to be insignificant (data not shown).
Discussion
Ru 486 is known to bind strongly to the glucocorticoid receptor with an
affinity three times higher than the potent glucocorticoid agonist dexamethasone
(205,209). But it also cross-reacts with the progesterone receptor and slightly with
the androgen receptor (209). Progesterone prevents glucocorticoid-induced
hypertension and potentiates natriuresis through its antimineralocorticoid activity
(210). Since progesterone possesses both antimineralocorticoid and
antiglucocorticoid properties, this led to the notion that RU 486 may possibly have
some antagonist or agonist mineralocorticoid activities as well (5). The results
presented here clearly indicate that RU 486 does not possess mineralocorticoid
antagonist or agonist properties. The lack of mineralocorticoid antagonist
property of RU 486 in terms of its prevention of DOCA-salt induced hypertension
is consistent with other

in vitro

studies suggesting that RU 486 has no cross

reactivity with mineralocorticoid receptors (209). According to Teutsch and
Costerousse the 17a-propynyl side chain provides RU 486 with pure glucocorticoid
activity devoid of mineralocorticoid activity and thus, this side chain may explain
the lack of binding of RU 486 to the mineralocorticoid receptor (213). In
addition, Grunfeld and Eloy (1985) have observed that sodium and potassium
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balance was not affected by RU 486 treatment in rats which indicates it has no
mineralocorticoid activity (125). On the contrary,

RU

486 administration

normalized the blood pressure and reversed the hypokalemic alkalosis seen in
Cushing's Syndrome patients (212). Since glucocorticoid- induced hypokalemic
effect is thought to be due to the mineralocorticoid activity of endogenous
glucocorticoids binding to Type I receptors in the kidney, it led to the speculation
that

RU

486 and/or some of its metabolites might possess some

antimineralocorticoid activity in man (212). Though studies have not been done in
human kidneys,

in vitro

studies have shown that

RU

486 has negligible cross

reactivity with the rat kidney mineralocorticoid receptors (209). Due to species
variability, it is necessary for similar study to be done in humans before any
conclusive remarks can be drawn. On the other hand, several researchers have
shown that the potent glucocorticoid agonist dexamethasone, with negligible
mineralocorticoid activity cross-react with the type I receptors in the brain
(184,214). However,

in vivo

physiological mineralocorticoid target tissues such as

the kidney, intestine and the parotid are highly aldosterone-selective, in contrast
with the hippocampus and heart (215). Thus, the binding of glucocorticoids to
type I receptors tends to be tissue specific.

In vitro

studies have shown high levels

of IIB-OH steroid dehydrogenase activity in these aldosterone-selective tissues,
but this enzyme has not been found in the hippocampus (216). This enzyme
converts glucocorticoids to its ll-dehydro metabolite which has a low affinity for
the type I receptor (217). This has been postulated as the mechanism by which
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glucocorticoids are excluded from binding to type I receptors in mineralocorticoid
target tissues (215).
Since RU 486 may not bind to kidney mineralocorticoid receptors, it is
more likely that the apparent antimineralocorticoid activity of RU 486 is not by its
binding to mineralocorticoid receptors in the rat kidney but rather indirectly
through its antagonism of glucocorticoid activity. Therefore, an antiglucocorticoid
preventing increased GFR will decrease the rate by which water and sodium pass
through the distal and collecting renal tubules and thus decrease water and sodium
retention giving the illusion of antimineralocorticoid activity. Results from this
laboratory (5) and others (212,218) have shown that RU 486 prevents the
transient diuresis and natriuresis induced by glucocorticoid treatment. RU 486
had no mineralocorticoid agonist property, since RU 486 did not potentiate the
blood pressure in the DOCA + RU 486 treated rats in spite of a possible increase
in plasma corticosterone level due to increased ACTH levels. Glucocorticoids
exert a negative feedback effect on ACTH secretion from the anterior pituitary
which serves as the major control mechanism of the pituitary-adrenocortical
system. Studies in humans and other primates have shown that RU 486 was able
to antagonize the suppressive effect of dexamethasone upon the pituitary-adrenal
axis (219,220). Thus, ACTH secretion is increased during RU 486 administration.
RU 486 treatment has been observed to activate the hypothalamic-pituitary
adrenal axis in rats and monkeys, as well as in humans (see 203 for review).
Chronic treatment with RU 486 in rats and monkeys resulted in increased ACTH
levels, adrenal weights and glucocorticoid levels (203). In humans, RU 486
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administration increased the ACfH secretion only at the times of the day when
endogenous corticotrophin-releasing hormone (CRH) was high, subsequently,
glucocorticoid levels were elevated in the early morning hours in Cushing's
Syndrome patients treated with RU 486 (208). Thus, though the corticosterone
level might have been increased in the DOCA + RU 486-treated rats, the
elevation in SBP between these rats and the rats treated with DOCA alone was
the same. This can be explained by the rationale that there were no receptors
available for corticosterone to bind as the type I receptor was occupied by excess
administration of DOCA and the type II by excess administration of RU 486.
DOCA given in combination with RU 486 resulted in a significant increase
in saline consumption followed by increased urine output. Mineralocorticoid
induced hypertension is characterized by increased saline intake. Structures in the
forebrain such as the anteroventral third ventricle (AV3V region) which is
involved in the regulation of thirst, sodium homeostasis, blood volume and the
secretion of arginine vasopressin (AVP) is necessry for mineralocorticoid
hypertension but not in the SHR (179,221). Lesioning of the AV3V region
prevents the development of this experimental model of hypertension in rats
(222). It is being hypothesized that mineralocorticoids may alter the intracellular
sodium content of the cells in the AV3V region and affect the release of other
agents that stimulate drinking. The plasma level of vasopressin is elevated in
DOCA-salt hypertension (222). The fluid consumption of rats treated with a
combination of DOCA and RU 486 was even higher than rats treated with DOCA
alone.

In vitro

studies have shown that RU 486 down regulates type 1 receptors in
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the mouse hippocampus ( 184). Since angiotensin stimulates fluid intake, RU 486
seems to behave as a weak agonist centrally (185) and the secretion of
vasopressin, we are postulating that RU 486 might be acting as an agonist in the
rat brain, thus potentiating the fluid consumption in these rats. This increase in
water consumption resulted in increased urinary output without any significant
change in the weight of the animals.
Though antiglucocorticoid RU 486 did not prevent the hypertension
induced by DOCA, surprisingly it enhanced the blood pressure of the SHR. Thus,
our finding contradicts the conclusion of Hashimoto et al. (85) that corticosterone
is essential for the development of hypertension in SHR. If this were to be the
case, RU 486 treated SHR should have shown a reduced rather than enhanced
blood pressure. It is important to point out that highly variable results have been
obtained regarding plasma levels of adrenocorticoids in SHR by various
investigators. Some have reported increased (82) or normal corticosterone (84)
levels and other have reported increased (86) or decreased aldosterone (226)
levels. Keeping this in mind, our results are consistent with the observation that
adrenalectomy of young prehypertensive rats prevented the increase in blood
pressure and subsequent infusion of aldosterone induced hypertension in these
rats (81), indicating that mineralocorticoids seem to be more important in the
induction of hypertension in the SHR model. To explain the enhanced blood
pressure observed in RU 486-treated SHR, we are postulating that in SHR, RU
486 was bound to type II receptors blocking glucocorticoid action while type I
receptors were unoccupied so that the excess corticosterone which might have
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been produced by RU 486 treatment (through activation of the hypothalamic
pituitary adrenal axis) could cross-bind to type I to exert biological effects
including increased blood pressure. This explanation agrees with Funder et al.
(215) suggesting that in peripheral mineralocorticoid target tissues such as the
kidney, aldosterone and corticosterone might have similar (patho) physiological
effect mediated by type I receptors provided that glucocorticods can gain access to
type I receptors. There seems to be an operational difference between Type I
receptors in the central nervous system and the periphery. Whereas the
aldosterone and corticosterone appear to have similar biological effect on blood
pressure when they bind peripheral Type I receptors, their effects mediated by
central Type I receptors are opposite ( 185).
In conclusion, RU 486 has no effect on DOCA-salt model of experimental
hypertension but significantly increased the hypertension in SHR suggesting that 1)
RU 486 specifically inhibits glucocorticoid-induced hypertension and 2) it is likely
that mineralocorticoids are involved in the development and maintenance of
hypertension in the SHR.
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Figure 1:

Effect of glucocorticoid agonist dexamethasone and the antagonist
RU 486 treatment on systolic blood pressure (SBP ) . Each point
represents mean ± SEM of six male Sprague-Dawley rats.
compared with control rats.

*p<O.05
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Figure 2:

Effect of mineralocorticoid agonist DOCA, and glucocorticoid
antagonist RU 486 treatment on SBP. Each point represents mean
± SEM of eight male Sprague-Dawley rats.
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Figure

3:

Effect of gluococorticoid antagonist RU 486 treatment on SBP of
spontaneously hypertensive rats (SHR). Each point represents mean
± SEM (n=8) . *p<O.05 compared with control rats.
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TABLE I
Effect of DOCA and DOCA plus R U 486 on body weight, water i ntake,
urine output and organ weig ht on Sprague-Dawley rats.

Control

DOCA

DOCA

+

RU486

Body Weight (gms)
day 0

305

± 3·6

307 · 9 ±

4·4

292

± 5·4

day 8

280

± 9·0

281

± 11 ·9

278

± 5·6

day 20

309

± 9·7

295

± 11 ·9

308

± 9· 1

Saline intake
( mljday)

21 · 8 ± 2 · 0

54 · 25 ± 2 · 8

14·5 ± 1 ·9

15·5

66 · 25 ± 3 · 5*

Urine volume
(m I/24h)

± 2 · 27

23

± 3 · 2*

Kidney weig ht (gms)

1 · 52 ±

· 082

1 · 98 ± 0 · 079

1 · 99 ± · 09

Heart weight (gms)

0 · 95 ±

· 037

1 · 005 ± 0 · 032

1 · 044 ± · 034

c.n
0-

TABLE I I
Effect o f R U486 treatment on weig ht, fluid i ntake,
urine vol u m e and organ weig hts o n spontaneously hypertensive rats (S H R ) .

Control

R U486 1 mg

R U 486 5mg

Body Weight (gms)
7 days

1 89 ± 4 · 9

1 93 ± 3 · 8

1 90 · 5

± 3·5

1 4 days

213 ± 3·9

232 ± 4 · 2

213

± 4·5

22 days

232 ± 4 · 1

240 ± 5 · 7

235

± 3·7

Water i ntake
(ml/day)

2 1 · 80 ± 0 · 87

2 1 · 30 ± 1 · 09

23 · 48 ± 1 · 3

Urine vol u m e
( m l/24h)

5 · 07 ± 0 · 42

5 · 1 7 ± 0 · 398

4·5

± 0 · 364
± 0· 18

Liver weight (gms)

8 · 8 ± 0 · 44

8 · 76 ± 0 · 43

9·2

Kidney weight (gms)

1 · 56 ±

· 039

1 · 78 ± · 01 3

1 ·71 ±

Heart weight (gms)

0 · 97 ±

· 035

0 · 87 ± · 032

0 · 928 ±

· 034

Thymus weight (gms)

0 · 24 ±

· 01 4

0 · 1 7 ± · 008

0 · 22 ±

· 0075

· 024

'"
....,

CHAPTER 2

The Role of the Mineralocorticoid Antagonist,
RU 26752 in Adrenocorticosteroid-Induced Hypertension
Abstract
The effect of mineralocorticoid antagonist RU 26752 on the development
and maintenance of hypertension produced by long-term administration of
mineralocorticoid agonist aldosterone has been investigated. Uninephrectomized,
saline-drinking male Sprague-Dawley rats were subcutaneously implanted with
either placebo (control) pellets, 100 J1.g aldosterone pellets, 50 mg RU 26752
pellets or 100 J1.g aldosterone + 50 mg RU 26752 pellets. Aldosterone treatment
resulted in an increase in blood pressure to 165
of 1 05

±

±

5 mmHg over the control value

2 mmHg within 3 weeks of experimental period. RU 26752 given alone

had no observable hypertensinogenic effect. However, RU 26752 administered
with aldosterone significantly prevented the hypertension produced by aldosterone
alone. RU 26752 when given with aldosterone was able to prevent the
aldosterone-induced increase in saline consumption, increase urine output and
reduce urinary Na+ excretion. Microscopic examination did not show any
significant lesions in either heart or kidney of the four groups examined. RU
26752 (7.5 mg or 15 mg) administered to Sprague-Dawley rats was unable to
58
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prevent hypertension produced by the administration of dexamethasone. The
results presented suggest that long-term administration of the
antimineralocorticoid

RU

26752 in vivo to Sprague-Dawley rats prevents the

aldosterone-induced hypertension and not dexamethasone-induced hypertension.
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Introduction
Presently, two steroidal aldosterone antagonists are being used clinically in
the treatment of mineralocorticoid excess diseases. The widely used
antimineralocorticoid is spironolactone. Spironolactone was the first competitive
aldosterone antagonist used as an orally active drug.
in vitro

studies show that spironolactone in ten times higher concentration is

needed to displace 3H-aldosterone from the receptor binding sites (202). This
suggests that the relative affinity of spironolactone

in vitro

compared to

aldosterone. Studies demonstrate that spironolactone also inhibits aldosterone
synthesis stimulated by ACTH, potassium or Ang II (223). Although the effect on
aldosterone synthesis is evident

in vitro,

the decrease in plasma and urinary

aldosterone levels during spironolactone treatment is only transient (223). Thus,
the natriuretic effect of spironolactone

in vivo

appears to be mainly due to its

antagonism of the mineralocorticoid receptors in the target tissues. However,
spironolactone is not specific for the mineralocorticoid receptor. It has affinity for
the androgen and progesterone receptors as well (202). This has resulted in
numerous endocrinological side effects with spironolactone treatment.
Spironolactone inhibits menstruation in rabbits, monkeys (224) as well as in
women (202) indicating a progestational activity of the drug. It also interferes
with the secretion and the peripheral action of androgens. Administration of large
doses of spironolactone causes a significant reduction in the synthesis of
testesterone (202). This effect may be due to spironolactone inhibiting the 17hydroxylase and 17-20-desmolase activities. This antiandrogenic effect of
spironolactone might explain the impotence and gynecomastia observed in men
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treated with spironolactone (224). Thus, the therapeutic value particularly during
long-term treatment with spironolactone is limited.
The second aldosterone antagonist used clinically is potassium canrenoate
which has been shown to possess a lower antiandrogenic activity in men (225).
However, the antimineralocorticoid potency of potassium canrenoate is lower than
that of spironolactone (202). In addition, the progestogenic potential of
canrenone, the active metabolite of potassium canrenoate, is higher than
spironolactone (227).
Therefore, both spironolactone and potassium canrenoate are far from
being the ideal aldosterone antagonists and the search for a more specific
mineralocorticoid antagonist with reduced adverse side effects has been necessary.
Several chemical modifications have been made on the spironolactone
molecule in search of a better mineralocorticoid antagonist with a markedly
reduced affinity for the androgen and progesterone receptors while the affinity for
the mineralocorticoid receptor is increased.
The affinity of 24 spironolactone analogues to the rat renal cytoplasmic
aldosterone receptor

in vitro

has been studied by Funder et al. (228). They

demonstrated a reduction in affinity for aldosterone receptor in analogues with 1)
unsaturation at CJC7 position in ring B; 2) unsaturation of the a-lactone; 3)
opening of the a-lactone ring. Substitution of the 7-a-thioacetyl group of
spironolactone by a propyl residue has yielded a compound designated RU 26752.
This compound is synthesized by scientists at Roussel-Uclaf. RU 26752 has been
shown to possess increased specificity for the mineralocorticoid receptor over
spironolactone (229). Interestingly,

in vitro

studies from this laboratory
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demonstrated that the kinetics of 3H-RU 26752-mineralocorticoid receptor
binding, suggested two classes of receptor sites in the rat kidney (230). One class
is of high affinity, low capacity in the 1-10 nM range followed by another class
with a low affinity high capacity range in the 10-100 nM 3H-RU 26752. The latter
class of receptors have little affinity for aldosterone. The increased specificity of
RU 26752 was confirmed by the observations that there was no binding to other
serum carriers from organs that are not a target for the mineralocorticoid
hormones and also by the lack of displacement of 3H-RU 26752 by cold steroids
(230). However, the correlation between the relative affinity of RU 26752 and its
in vivo

pharmacological activity is not known. Therefore, this study was

conducted to confirm the

in vitro

studies demonstrating increased specificity of RU

26752 to the mineralocorticoid receptor. For the first time, the effect of long
term

in vivo

administration of this novel synthetic compound on the development

and maintenance of aldosterone-induced hypertension in rats was studied. Further
studies were conducted to show if RU 26752 prevents only mineralocorticoid
induced hypertension without exhibiting any glucocorticoid agonist or antagonist
properties by its effect on dexamethasone-induced hypertension.
Materials and Methods
For initiating aldosterone-induced hypertension, animals were right
mononephrectomized under ether anesthesia and maintained on Purina Chow
and 1 % saline

ad libitum.

A week after mononephrectomy, a small incision under

ether anesthesia was made and custom-made pellets containing either placebo
(n= 6), 100 !log aldosterone (n= 6), 50 mg RU 26752 (n= 6) or 100 !log aldosterone
plus 50 mg RU 26752 (n= 6) were inserted subcutaneously.

Custom pellets were

63
used to deliver the constant dose of steroid agonist, antagonist and combination of
agonist and antagonist. The pellets were obtained from Innovative Research of
America (Toledo, OH). These pellets conveniently released the desired drug
vivo

in

within three weeks in a controlled dose-dependent manner.
For initiating dexamethasone-induced hypertension, four groups of rats

(n= 8) were given 1M injections of either 0.2 ml olive oil/300 gm, 1.5 mg
dexamethasone/300 gm, 1.5 gm dexamethasone + 7.5 mg RU 26752/300 gm or 1.5
mg dexamethasone + 15 mg RU 26752/300 gm, dissolved in 0.2 ml olive oil every
third day for 18 days (total 7 injections).
Systolic blood pressure (SBP) was measured on days 0, 7, 14 and 21. The
body weight, water intake and urine output were monitored. The Na+
concentration in the urine was measured by flame photometry. At the end of the
experimental period, the animals were exposed to carbon dioxide and immediately
killed by cervical dislocation. The organs were removed quickly and weighed. The
kidney and heart tissues were preserved in formalin and histological preparation
was done later for morphological examination. Analysis of variance was carried
out and means were analyzed by Scheffe contrasts for comparison.
Experiments conducted with the SHR were not successful and due to drug
and animal constraint, the experiment could not be repeated.
Results
First, we determined the optimum dose of aldosterone required to produce
a significant increase in blood pressure in mononephrectomized, saline drinking
rats. It was observed that 100 J.Lg aldosterone pellets gave a significant increase
in blood pressure (162

±

4 mmHg) over control animals ( 107

±

2 mmHg) within a
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three-week period (data not shown). Therefore, 100 J.lg aldosterone pellets were
used in subsequent experiments. Next, we determined the optimum dose of RU
26752 needed to antagonize the hypertension produced by the 100 J.lg aldosterone
pellet (which delivered about 5 J.lg aldosterone/day). Mononephrectomized saline
drinking rats were subcutaneously inserted with 100 J.lg aldosterone pellet and then
daily injected with either 500 J.lg, 1 mg or 2.5 mg RU 26752 in 0.2 ml olive oil for
three weeks. We noted a significant decrease in the blood pressure in the
aldosterone-treated animals injected with 2.5 mg of RU 26752 along with 100 J.lg
aldosterone. Results obtained with 50 mg of RU 26752 pellet (which releases 2.5
mg RU 26752/day) are therefore presented in Figure 4. This figure shows the
differences among control, aldosterone, RU 26752 and aldosterone plus RU
26752-treated rats over three weeks. While the blood pressure of
mononephrectomized, saline-drinking control and RU 26752-treated rats was
slightly increased, blood pressure was significantly elevated in the aldosterone
treated ( 165

±

5 mmHg) as compared to control rats ( 105

±

3 mmHg). This

increase was significantly prevented by simultaneous administration of
antimineralocorticoid RU 26752 with aldosterone ( 1 12

±

4 mmHg).

Data presented in Table III show that there was no significant difference in
weight gain among the four groups. Saline intake and urinary excretion of water
were higher during 11 and 18 days in aldosterone-treated rats as compared to
control rats. On the other hand, RU 26752 and RU 26752 plus aldosterone
treated animals maintained water intake and urinary output at the level of control
animals.
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Urinary sodium excretion was found to be significantly reduced in the
aldosterone-treated animals on day 11 but returned to control level on day 18
(Table III). No significant changes in urinary Na+ excretion were noted in RU
26752 or RU 26752 plus aldosterone-treated animals as compared to control
animals. Microscopic examination of the hearts and kidneys from the four
experimental groups showed no significant abnormalities.
Results presented in Figure 5 demonstrates that dexamethasone treatment
to Sprague-Dawley rats resulted in a rapid increase in the blood pressure. By day
18, dexamethasone-treated animals had attained a blood pressure of 158
compared to 118

±

±

4

4 observed for the control (untreated) animals. RU 26752 at

either 5 times or 10 times the amount of dexamethasone (1.5 mg) was unable to
reverse the hypertension produced by dexamethasone during the three-week
experimental period (Fig. 5). Dexamethasone-treated animals lost significant
weight during three weeks of steroid administration and RU 26752 has no
significant effect on reversing the observed weight loss induced by dexamethasone
(Fig. 6).
Dexamethasone treatment resulted in increased water consumption, urinary
output, and a decrease in liver, kidney, heart and thymus wet weight over control
untreated animals (Table IV). RU 26752 at two different doses given in
combination with dexamethasone was unable to reverse any of the above effects
induced by dexamethasone treatment.
Discussion
Although DOCA-salt is a well-established model of experimental
mineralocorticoid hypertension in the rats, we have chosen aldosterone
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administration combined with high salt intake and reduced renal mass as a model
for mineralocorticoid-induced hypertension in the present study. We have chosen
aldosterone-induced hypertension because the majority of clinical
mineralocorticoid-dependent hypertension is due to an excess of aldosterone and
not DOC (3). Though hypersecretion of DOC occurs in congenital adrenal
hyperplasia (CAR), such cases are very rare (9). Moreover, very large doses of
DOC which is wel1 above physiolgoical levels is required to induce
mineralocorticoid hypertension in experimental animals. Since this is the first time
the antimineralocorticoid

RU

26752 was being used to antagonize the

in vivo

actions of mineralocorticoids we thought it necessry to use a more potent
mineralocorticoid, aldosterone which is needed in microgram quantities to induce
hypertension as compared to milligram quantities of DOCA ( 174-176). Other
researchers have used aldosterone infusion to show a dose-dependent change in
blood pressure of rats (9). Some studies show that the hypertensinogenic potency
of aldosterone is superior to DOC in the rat as hypertension is produced by the
administration of aldosterone doses which results in plasma levels no greater than
that caused by stress (23 1).
In this study, we present evidence suggesting that aldosterone-induced
hypertension in uninephrectomized salt-drinking Sprague-Dawley rats can be
prevented by the simutaneous administration of the antimineralocorticoid RU
26752. While an effective dose ratio of 1 Jl.g aldosterone: 26.8 mg spironolactone
has been reported in rats (232), we have shown in this study a ratio of I Jl.g
aldosterone; 0.5 mg
hypertension in rats.

RU

26752 to be effective in preventing aldosterone-induced

RU

26752 unlike the antialdosterone potassium prorenoate
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which had a higher affinity for the mineralocorticoid receptor than spironolactone
in vitro

but was shown by Funder et al. to have a very low affinity for the receptor

in vivo

(228). This confirms the

in vitro

studies demonstrating that RU 26752

binds the mineralo �orticoid receptor with greater affinity and specificity than that
of spironolactone (229).
However, a rather high concentration of RU 26752 is still neeeded to
antagonize the hypertensive effect of aldosterone

in vivo.

The ratio of aldosterone

to RU 26752 is 1 :500. In this regard, it is interesting to note that Lazar and
Agarawal (230) reported a distinct anti-mineralocorticoid binding site in rat kidney
which was physicochemically different from the well-characterized
mineralocorticoid receptor in various target tissues. They showed evidence for a
mineralocorticoid receptor with low affinity, high capacity that binds antagonist but
not agonist. Therefore, it is likely that

in vivo,

a larger amount of RU 26752 is

needed to exert its effect on high affinity aldosterone binding sites. Alternatively,
it is possible that RU 26752 may be converted

in vivo

to a metabolite(s) with

reduced biological activity therefore larger amounts are required.
Aldosterone when given alone significantly increased saline consumption
and urinary output with low Na+ excretion compared to control animals.
Increased saline intake and subsequent polyuria characteristic of mineralocorticoid
hypertension have been shown in several studies (179,221,222). In all these
studies the AV3V region of the brain which regulates thirst, sodium balance and
blood pressure has been implicated. Destruction of the AV3V region has been
shown to reverse hypertension caused by mineralocorticoids and high salt intake
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(179,221). However, Gomez-Sanchez has suggested that the prevention of
DOCA-salt hypertension by the lesioning of AV3V region may be due to
destruction of specific pressor functions and not so much as the destruction of
thirst and salt appetite centers (233). On the other hand, many studies have
demonstrated that mineralocorticoid hypertension does not develop if sodium
intake is restricted ( 120, 121, 124) and therefore the salt appetite center is
important in this model of experimental hypertension. RU 26752 administered
together with aldosterone reversed the increase in saline consumption and Na+
retention induced by aldosterone. RU 26752 was devoid of any pressure effect
when given alone and had no effect on either saline consumption, diuresis or on
Na + excretion. Thus, RU 26752 seems to have no mineralocorticoid agonist
properties

in vivo.

Also RU 26752 was observed to have no deleterious effects

when given alone or together with aldosterone on either kidney or heart as noted
under microscopic examination. Morphological examination of the heart and
kidney tissues is relevant in assessing the toxic side effects of these steroid
hormone antagonists as antihypertensive drugs. It is a well-established clinical fact
that a sustained and signficant reduction in arterial pressure is followed by the
development of heart failure or myocardial infarction in hypertensive patients
(234). In addition, experimental myocardial infarction in SHR was associated with
prolonged reduction in blood pressure (235). The side effect from most
antihypertensive drugs is renal failure and the histology is that of acute interstitial
nephritis (236).
It is important to know whether RU 26752 is specific for mineralocorticoid
induced hypertension or it also has glucocorticoid antagonist properties. Our
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results suggest that RU 26752 administered at 7.5 mg (5x the dose of dex) or even
at 15 mg (lOx dose of dex comparable to dose of RU 486 by ratios) is devoid of
any glucocorticoid agonist or antagonist properties as it had no effect on
glucocorticoid-induced hypertension. Thus

RU

26752 seems to possess pure

antimineralocorticoid properties in terms of its hypertensive effects in steroid
induced hypertension.
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Figure 4:

Effect of mineralocorticoid agonist aldosterone and antagonist RU
26752 treatment on SBP. Each point represents the mean ± SEM
of two separate experiments using Sprague-Dawley rats (n=6) in
each experiment. *p<0.05 compared with control rats.
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Figure 5:

Effect of mineralocorticoid antagonist RU 26752 on dexamethasone
induced hypertension. Each point represents the mean ± SEM using

Sprague-Dawley rats (n=8 ) in each group.
control rats.

*p<O.05 compared with
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Figure 6:

Body weight in dexamethasone and dexamethasone plus RU 26752
treated rats. Each point represents the mean ± SEM using Sprague
Dawley rats in each group. *Significant differences from
corresponding value in control untreated animals (P < .05).
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Tab l e I I I

E f fe c t o f m in e r a l o c o r t i c o i d agon i s t a l d o s t e rone and antagoni s t RU 2 6 7 5 2
t r e a tmen t o n b o dy we i gh t , s a l ine i n t ake , urine output and e x c r e t i on o f s o d 5.um .

Days a f t e r t r e a tme nt
B o dy We i gh t ( g )
Contro l
A l do s te rone
RU/2 6 5 7 2
RU/ 2 6 7 5 2 + A l do s te rone

11

0

IS

2 4 S±7
2 5 2±6
2 6 1± 7
2 7 4±9

2 2 5±6
2 3 4±S
2 2 S±S
242±10

2 S 2±4
3 0 4±4
2 S 0± 5
3 0 6± 7

S a l ine I n t ake ( ml / 2 4 h )
Contro l
A l do s t e rone
RU/ 2 6 7 5 2
RU/ 2 6 7 5 2 + A l do s t e rone

2 S±2 . 1
2 9±2 . 6
3 1 . 2±3 . 1
2 6 . 4±2 . 4

30 .
*52 .
35 .
3S .

2±2
2±1
2± 1
S±2

.
.
.
.

6
S
6
1

3S
" 51
36
39

.
.
.
.

6±3
2±2
1±3
2±1

.
.
.
.

2
8
1
S

16
17
15
17

14 .
*24 .
lS .
19 .

3±1
S±3
2±1
3±1

.2
.2
.6
.4

17
" 31
17
19

.
.
.
.

1±1
2±4
6±1
5±1

.
.
.
.

5
1
S
3

. 4±O .
. 1±O .
. 7±O .
. 4±O .

2
2
2
1

U r i ne o u t p u t ( m l/24h )
Contro l
A l do s t e r o n e
RU/ 2 6 7 5 2
RU/ 2 6 7 5 2 + A l d o s t e r one

. 8±1
. 6±2
. 2±1
. 4±2

.6
.1
.4
.1

S o d ium ( me q/ 2 4h )
Control
A l do s t e r one
RU/ 2 6 7 5 2 .
RU/2 6 7 5 2 + A l do s t e rone

2
2
2
2

. 4±O .
. 6±O .
. 6±O .
. 4±O .

3
3
1
3

2 . S±O .
* 1 . 7±O .
2 . 4±O .
2 . 2±O .

2
1
3
2

2
2
2
2

V a l u e s exp r e s s e d a r e m e an ± S EM ( n�6 ) .
* S i gn i f i c a n t d i ffe rence from c o r r e s p onding value i n c o n t r o l unt r e a t e d a n i ma l s
( P<O . 0 5 )
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TABLE IV

E f fe c t of g l uc o c o r i t o c i d agoni s t , dexame thasone and m i n e r a l o c o r t i c o i d a n t a g o n i s t
RU 2 6 7 5 2 t r e a tm e n t o n f l u i d i n take , u r i n e vo lume and o r gan we i gh t s .

control

Dex
1 . 5mg

RU2 6 7 5 2
7 . 5mg
+

Wa t e r I n t ake
( m l /day )

3 2 . 8±0 . 8 2

U r i ne o u t p u t
( m l / 2 4h )

1 1 . 8 5±0 . 6 4

Liver we i gh t

1 4 . 1 6 ±0 . 6 7

K i dney we i gh t
Heart

we i gh t

'40 . 7 5±1 . 2 6

' 2 1±0 . 8
' l O . 5±0 . 2 5

Dex
1 . 5 mg

'43±1 . 6

'40 . 7 5±1 . 2

' 1 7±3 8
' 1 1 . 1 6±0 . 5

' 2 . 3 5± . 01,

' 2 . 5± . 0 8

1 . 2 9± . 0 5

'O . 9 8± . 0 5

' 1 . 0 0 5 ± . 04

Thymus we i gh t

0 . 4 9± . 0 2 8

'O . 2± . 0 2 4

'O . 1 9 8± . 0 1 6

Adr e n a l we i gh t

. 0 7 l± . 0 0 6

. 0 3 7± . 0 0 2

' 0 . 04± . 0 0 4

*P<0 . 0 5 c ompa r e d w i th c o n t ro l .

+

Dex
1 . 5 mg

3 . 1 4± . 9 6

Value s e x p r e s s e d are m e a n ± S EM ( n�8 )

RU 2 6 7 5 2
1 5 mg

' 2 1 . 7±0 . 6
' 1 1 . 04±0 . 2 3
' 2 . 3 5± . 0 8
'0 . 9 4 5± . 0 2 6
'0 . 2 5 4± . 0 2
' 0 . 0 3 6± . 0 0 2 4

CHAPTER 3

The Role of the Novel Antimineralocorticoid, Mespirenone, on
Adrenocorticosteroid-Induced Hypertension
Abstract
The effects of the aldosterone antagonist mespirenone on the development
and maintenance of hypertension in three different experimental models of
hypertension were studied. Uninephrectomized saline-drinking male Sprague
Dawley rats injected i.m. with either 0.2 ml olive oil (control), 50 J.Lg aldosterone, 1
mg mespirenone, 50 J.Lg aldosterone plus 500 J.Lg mespirenone or 50 J.Lg aldosterone
plus 1 mg mespirenone, each dissolved in 0.2 ml olive oil. Administration of
aldosterone alone significantly increased the systolic blood pressure (SBP) from a
control value of 114

±

3.6 to 162

±

4 by the end of the three-week experimental

period. Mespirenone given alone had no effect on SBP. However, mespirenone
given in combination with aldosterone reversed the hypertension caused by
aldosterone in a dose-dependent manner.

Saline consumption and urinary output

were slightly increased in aldosterone-treated rats as compared with the other
groups but the body weight and organ weights were comparable in all groups.
Also microscopic examination of kidney and heart showed no abnormalities. On
the other hand mespirenone was unable to prevent the dexamethasone-induced
78
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hypertension. Instead, the blood pressure was slightly increased (169

3.3) when

±

mespirenone was administered simultaneously with dexamethasone as compared
to dexamethasone alone ( 142

±

3.0). Interestingly, mespirenone potentiated

dexamethasone-induced thymic involution and was unable to reverse the body
weight loss resulting from dexamethasone treatment. However, the kidney and
heart weights were not affected by mespirenone treatment. SHR animals were
given two different doses of mespirenone. At the end of the three-week
experimental period, rats injected with 2.5 mg mespirenone showed a reduction in
SBP (198.3

±

3.6) compared to control SHR given only olive oil (215.2

±

2.8) and

rats injected with 5 mg mespirenone demonstrated a further reduction in the SBP
( 190.0

±

2.6). However, statistical analysis of the data showed no significant

difference between SHR treated with mespirenone and control SHR. These
results suggest that the

in vivo

administration of mespirenone to rats (i) effectively

prevents the aldosterone-induced hypertension and (ii) had no effect on
dexamethasone-induced hypertension. (iii)

As

compared to glucocorticoids, it is

suspected that mineralocorticoids may be more involved in the development of
hypertension in the SHR.
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Introduction
Though different chemical substitutions have been made on the
spironolactone molecule in the hope of decreasing its antiandrogenic and
progestogenic activities while at the same time increasing its anti-aldosterone
potency, no new steroidal anti-mineralocorticoid has been introduced into the
therapy of aldosterone-dependent diseases. Studies have shown that the
introduction of a 1,2 double bond into the spironolactone molecule leads to a
reduction in the affinity for the androgen and progesterone receptors without
changing the antimineralocorticoid potency in

vitro

(237). Additional modifications

introducing a 15, 16-methylene moiety significantly increased the
antimineralocorticoid potency (238). Such a compound with chemical
modifications of a 1,2 double bond and 158, 168 methylene ring on the
spironolactone molecule has been synthesized by researchers at Schering and it is
known as mespirenone (72-acetylthio-158, 168-methylene-3-oxo-17 a-pregna-l,4diene-21, 17-carbolactone). In animal studies mespirenone exhibited a three-times
greater antiandosterone potency and less than 10% of the antiandrogenic activity
of spironolactone (238). In these studies, the antimineralocorticoid effect of
mespirenone was assessed by its ability to reverse the renal action of aldosterone
which is the sodium retaining and potassium diuretic effect.
In humans, Seibert et al. reported that the antimineralocorticoid potency of
mespirenone following oral administration was about six times higher than
spironolactone (239). From a therapeutic point of view, an increase in
antimineralocorticoid potency of a new aldosterone antagonist by itself is
desirable. Moreover,

in vivo

studies in humans showed no progestogenic activity
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of mespirenone even at pharmacological doses (240).

Thus, rnespirenone

appears to be the aldosterone antagonist that researchers have been searching for.
However, up until now the

in vivo

studies involving mespirenone have focused on

its natriuretic property and its endocrinological profile. Since one of the most
common complications of excess mineralocorticoids is hypertension, it is necessary
to study the

in vivo

effect of mespirenone on hypertension in assessing its anti

mineralocorticoid potency. Therefore, for the first time, a long-term study of the
antihypertensive effect of rnespirenone on three different experimental models of
steroid-induced hypertension was conducted.
Materials and Methods
Three experiments were conducted to study the role of mespirenone in
steroid-induced hypertension. To initiate aldosterone-salt-induced hypertension,
Sprague-Dawley rats were uninephrectomized under ether anesthesia and given
0.9% saline. One week later, the rats were divided into five groups each
containing six rats (n= 6). They were injected every other day over a period of 18
days. Group I was given 0.2 rnl olive oil (control), Group II received 50 J.Lg
aldosterone/300g, Group III was treated with 1 mg mespirenone/300g, Group IV
with a combination of 50 J.Lg aldosterone and 500 J.Lg mespirenone/300g (10 times
the dose of aldosterone), and Group V with a combination of 50 J.Lg aldosterone
and 1 mg mespirenone/300 (20 times the dose of aldosterone). Aldosterone and
mespirenone doses for these experiments were chosen based on dose-response
studies done previously in this laboratory (unpublished data).
To induce dexamethasone hypertension, Sprague-Dawley rats were divided
into four groups with eight rats in each group (n= 8). Group I was injected with
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0.2 ml olive oi1/300g, Group II with 1.5 mg dexamethasone/300g, Group III with
both 1.5 mg dexamethasone and 15 mg mespirenone/300g (10 times the dose of
dexamethasone), and Group IV received 1.5 mg dexamethasone and 30 mg
mespirenone/300 (20 times the dose of dexamethasone).
SHR animals were divided into three groups with eight rats in each (n= 8).
Group I was injected with the vehicle 0.2 ml olive oil, Group II with 2 mg
mespirenone/150g and Group III 5 mg mespirenone/150g dissolved in 0.2 ml olive
oil.
Baseline systolic blood pressure (SBP) was measured before steroid
administration and then once a week thereafter.

An

average of six to eight blood

pressure measurements within 5 mmHg of each other was used as the
representative SBP for each animal. The mean body weight was taken over 6 to 8
readings and this represented the body weight of each rat. Fluid consumption and
urinary output over a 24-hour period were collected on two consecutive days each
week. At the end of each experiment, the rats were anesthetized with carbon
dioxide and quickly killed by cervical dislocation. The heart, kidney, liver and
thymus were removed and weighed. Histological preparations were done with the
heart and kidney tissues for morphological examinations of any possible lesions
due to hormone antagonists treatment. Data were analyzed by the two-way
analysis of variance followed by the Scheffe test for multiple comparisons.
Results
Results presented in Figure 7 show a very rapid increase in the blood
pressure of aldosterone-treated rats over control rats within a week of steroid
administration and remained throughout the experimental period. This increase in
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the blood pressure was completely prevented by the mineralocorticoid antagonist
mespirenone given simultaneously with aldosterone. Five hundred (500) J.Lg of
mespirenone given together with 50 J.Lg of aldosterone reduced the SBP from 162
±

3.4 (aldosterone-treated value) to 126

reduced it to 116

±

±

3.4 and 1 mg mespirenone plus 50 J.Lg

1.9 which was similar to the control value ( 1 14

±

3.6).

Data presented in Table V indicate no significant change in body weight in
all five groups. Although saline consumption was higher in the aldosterone
treated rats, this was followed by a correspondingly higher urinary output.
However, the simultaneous administration of mespirenone with aldosterone
maintained saline intake and urinary output at the level of the control animals.
There was no significant difference in the organ weights among the groups (Table
VI). Microscopic examination of the kidney and heart showed no significant
lesions. Microscopic changes were limited to minimal focal myocyte fuchsinophilia
of the myocardium which is considered to be insignificant (Data not shown).
Results shown in Figure 8 demonstrate a rapid and significant increase in
blood pressure within a week of dexamethasone treatment which continued until
the end of the experiment. Mespirenone at two different doses given in
combination with dexamethasone was unable to prevent the hypertension induced
by dexamethasone treatment. Surprisingly, the blood pressure of rats treated with
a combination of dexamethasone and mespirenone ( 160

±

3.6; 169

higher than rats treated with dexamethasone alone ( 142

±

2.5) but the difference

±

3.5) was

was not statistically significant. Thus, mespirenone seemed to have potentiated
dexamethasone-induced hypertension.

As

observed in Table VII a three-week

dexamethasone treatment significantly decreased the body weight (289.5

±

9.0) as
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compared to controls (372.6

±

7.9) and mespirenone was unable to prevent this

weight loss (291.5

±

13.6). Interestingly, simultaneous administration of

±

8.0; 300

mespirenone and dexamethasone resulted in complete involution of the thymus
while dexamethasone administered alone caused a partial involution of the thymus
(Table VII). However, heart and kidney weights were not affected by the
treatment and no abnormalities were found in the hearts and kidneys of the
treated groups under microscopic examination. Water intake and urinary output
were comparable in all groups (Table VIII).
Data presented in Figure 8 demonstrate that mespirenone does not prevent
hypertension developed by SHR. Although the SBP of the rats treated with
mespirenone at two different doses (198
to control SHR (215.2

±

±

3.6; 190.5

±

2.6) was lower compared

2.8), the difference was not statistically significant. There

was no significant change in body weight, water intake, urinary output and organ
weights between control SHR and mespirenone-treated SHR animals (Table VII).
Discussion
The results obtained show that aldosterone administered to
mononephrectomized saline-drinking rats leads to the development of
hypertension. This hypertension can be prevented by the simultaneous
administration of the potent mineralocorticoid antagonist, mespirenone with
aldosterone. To our knowledge, this is the first study to look at the
antihypertensive effect of long-term treatment with mespirenone combined with
aldosterone. The potency of this aldosterone antagonist can be appreciated when
this study is compared with studies involving other mineralocorticoid antagonists.
Results in the previous study show that the newly synthesized
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antimineralocorticoid RU 26752 by Roussel Uelaf, prevents aldosterone-induced
hypertension in Sprague-Dawley rats (241). However, very high doses of RU
26752 were needed to effectively prevent aldosterone-induced hypertension as
compared to mespirenone. To antagonize aldosterone-induced hypertension,
studies show that an optimum dose of RU 26752 five hundred times more than
the dose of aldosterone which caused an increase in the blood pressure was
needed, whereas only ten times the dose of the same amount of aldosterone was
needed for mespirenone. Studies involving spironolactone show that even a
higher dose than RU 26752 was employed to antagonize mineralocorticoid actions
in vivo

(232). In rats, a dose of spironolactone as high as 26.8 mglkglhr is

administered to counteract aldosterone action in

vivo

(232). In patients with

mineralocorticoid-excess diseases, a dose of 200-400 mg/day of spironolactone is
given (193). Therefore, the reduction of the therapeutic dose of mespirenone will
not only be economically advantageous but will offer less chance of side effects.
Preliminary studies have been done by other researchers to evaluate the
natriuretic effect of mespirenone and observed a three-times higher potency in
rats (238) and a six-times higher potency in humans (239) as an
antimineralocorticoid than spironolactone. Unlike spironolactone, mespirenone
has been shown to have no progestational activity after two weeks of treatment in
humans (239) and a markedly reduced antiandrogenic activity (238). Thus, the
potency of mespirenone as a mineralocorticoid antagonist with reduced
endocrinological side effects is well established. However, the possibility of
mespirenone possessing some weak mineralocorticoid agonist activity has not been
investigated until now. It is well known that steroid antagonists may also possess
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some steroid agonist properties and are known as suboptimal antagonists (203).
According to these results, rats given mespirenone alone showed a slight increase
in the blood pressure over control rats. This is consistent with other steroid
antagonists such as RU 486 which was shown by a study in our lab to possess
some weak glucocorticoid agonist properties in the early phase of administration
(5). However, since the increase in blood pressure of the rats treated with
mespirenone alone was not statistically significant, this slight elevation might be
due to variabilities in that group and not due to mespirenone treatment.
Surprisingly, the simultaneous administration of mespirenone and
dexamethasone caused a complete involution of the thymus. The reason for this
observation, (mespirenone potentiating dexamethasone-induced thymic involution)
was unexpected and seems to indicate that mespirenone may have some
glucocorticoid agonist activity since glucocorticoid-induced thymic involution is
known to be a Type II-mediated mechanism. But this was proved not to be the
case as results from another experiment in our lab showed that glucocorticoid
receptors were not down regulated by mespirenone. Thymus weight was not
affected by mespirenone treatment in the other groups and microscopic
examination of the kidney and heart tissues showed no abnormal lesions due to
mespirenone treatment.
Thus, mespirenone is a novel mineralocorticoid antagonist which might
offer clinical advantages over spironolactone in the treatment of mineralocorticoid
exces diseases such as mineralocorticoid-induced hypertension with far less
deleterious endocrinological side effects.
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Figure 7:

Effect of the mineralocorticoid agonist, aldosterone and
mineralocorticoid antagonist, mespirenone, treatment on SBP of
Sprague-Dawley rats. Each point represents the mean ± *P < O.05
compared with control rats.
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Figure 8:

Effect of glucocortcoid agonist, dexamethasone, and the
mineralocorticoid antagonist, mespirenone, treatment on SBP. Each
point represents mean ± SEM of eight male Sprague-Dawley rats.
*P< O.OS compared with controls.
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Figure 9:

Effect of mespirenone treatment on systolic blood pressure of
spontaneously hypertensive rats (SHR). Each point represents
means ± SEM of eight rats.
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TAB L E V

Body we i g h t ,

s a l i n e con s umpt i on and u r i n e o u t p u t i n r a t s treated w i t h a l d o s terone and a l d o s terone p l u s

mes p i renon e .

Al d o + 1 0 x M e s o

Control

Al d o

Me s o

d ay 0

289 ± 5 . 6

284 ± 4 . 9

273 ± 4 . 7

281 ± 2 . 5

282 ± 3 . 9

d ay 7

343 ± 7 . 8

303 ± 1 3 . 7

299 ± 8 . 8

334 ± 5 . 4

308 ± 9 . 4

d ay 1 4

341 ± 3.5

322 ± 5 . 2

327 ± 2 . 2

369 ± 4 . 2

314 ± 10 . 0

d ay 2 1

405 ± 6 . 9

388 ± 5 . 9

380 ± 7 . 2

Al do + 2 0 x M e s o

Body we i g h t ( g m s )

317 ± 4 . 5

362 ± 9 . 5

U r i n e out put
(ml/24hr)

25 ± 1 · 8

* 34

± 1·4

24 ± 2 · 0 5

28 · 0 ± 2 · 4

23 · 0 ± 3 · 3

48 · 3 ± 3 · 4

42 · 6 ± 2 · 1

40 · 3 ± 3 · 1

S a l i n e c o n s u mpt i o n
(ml/24hr)

36 · 41 ± 1 · 6

* 45 · 9

± 2·4

<D
'"
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TABLE V I
E f fe c t o f gluc o c o r t i c o i d agon i s t I dexame tha s one and m i n e r a l o c o r t i c o i d
a n t a g o n i s t , me s p i renone t r e a tment on b o dy we i gh t a n d o r gan we i gh t s .
T r e a tme n t G r o u�s
Contro l

Dex

Dex

Dex

+

+

( l Sm g M S P )

30mg MSP

B o dy We i gh t ( gm )
Day 0

316 · 8 ± 4 · 5

3 34 · 8 ± 6 · 3

3 30 · 3 ± 3 · 9

3 30 · 6 ± 3 · 3

Day

347 · 5 ± 3 · 9

299 · 6 ± 6 · 7

303 · 2 ± 6 · 5

290 · 5

±

Day 1 7

372 · 6 ± 7 · 9

2 8 9 · 5 ± 9 · 0*

291 · 5

300

± 1 3 · 6**

±

8 · 0"

9·0

Wa t e r i n t ake
( ml / 2 4 h r )

39 . 5 ± 5 . 1

41 . 5 ± 4 . 6

37 . 4 ± 3 . 8

15 . 6 ± 2 . 6

13 . 3 ± 2 . 3

15 . 8 ± 2 . 1

42 . 0 ± 2 . 4

U r i n e v o l ume
( m l / 2 4h r )

Thymus

mg

3 /, O m g ±

50

87

±

15 . 5 ± 1 . 7

20

Hear t , mg

1 , 180

± 80

1 , 000 ± 30

1 , 050 ± 30

1 , 01, 0 ± 4 0

K i dney , m g

2 , 940

± 250

2 , 800 ± 1 1 0

2 , 6 70 ± 100

2 , 980 ± 110
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Table VII
Effect of Mespirenone Treatment on Body Weight, Water Intake,
Urine Output and Organ Weight of Spontaneously Hypertensive rat (SHR)
Control
Body Weight (g)

( 2.5 mg)

Mespirenone

Mespirenone
(5 mg)

Day 7

337

±

4.3

336

±

2.5

339

±

6.2

Day 14

343

±

5.7

337

±

4.1

334

±

8.5

Day 21

361

±

4.3

351

±

3.7

345

±

7.5

Saline Intake
(ml/day)

28.3

±

2. 1

23.0

±

1.8

32. 1

±

3.2

Liver weight (g)

13.5

±

0.4

14.3

±

0.2

15.1

±

1.1

Kidney weight (g)

2.8

±

0.07

3.0

±

0.04

3.1

±

.17

Heart weight (g)

1.5

±

0.04

1.5

±

0.02

1.5

±

0.12

CONCLUSION

From the results presented in this study, RU 486 seems to be a potent
glucorticoid antagonist without any effect on mineralocorticoid hypertension.
Thus, RU 486 may have potential clinical use in the treatment of glucocorticoid
induced hypertension, the most common complication associated with
glucocorticod excess diseases such as Cushing's Syndrome.
Although the mineralocorticoid antagonist spironolactone, is clinically used
in the treatment of mineralocorticoid excess diseases, it is limited by numerous
adverse endocrinological side effects. Accoridng to the results presented here,
mespirenone appears to be a better substitute for spironolactone than RU 26752
in the treatment of mineralocorticoid excess diseases. Not only was a far less
amount needed to antagonize the

in vivo

actions of aldosterone but also,

mespirenone has been shown by others to have negligible side effects associated
with spironolactone.
This work has established these three novel steroid hormone antagonists as
potent and specific in

vivo.

Apart from their potential therapeutic use as

discussed above, steroid hormone antagonists can be used as tools to probe the
molecular mechanism of action of steroid hormones about which little is known.
At this point, it is known that the steroid hormones exert their biological effects by
96
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regulating gene expression in the cells of the target tissues. Due to the recent
availability of cDNA for both the glucocorticoid and mineralocorticoid receptors,
work has begun in our lab to measure the glucocorticoid receptor and
mineralocroticoid receptor expression during steroid-induced hypertension and
during the inhibition of hypertension by these antagonists. This is consistent with
my objective to explore the molecular mechanism by which steroid hormones
induce hypertension as more cDNA probes of other steroid-hormone target genes
become available in the future.

APPENDIX
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APPENDIX A
Table VIII
Effect of the Mineralocorticoid Agonist, DOCA, and the Glucocorticoid
Antagonist, RU 486, on Systolic Blood Pressure
Week of Treatment
Second

Third

3.6

127.5

±

1 19.3

±

4. 1

±

3.6

170

2.8

173.6

±

1.6

±

2.4

173.6

152

3.6

Treatment Groups

First

Control

1 19.0

±

1 mg DOCA

120.5

1 mg DOCA +
10 mg RU 486

121.7

±

±

3.5

1.6

±
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APPENDIX B
Table IX
Effect of the Glucocorticoid Antagonist, RU 486 Treatment
on the Systolic Blood Pressure of Spontaneously Hypertensive Rats (SHR)
Week of Treatment
Second

Treatment Groups

First

Control

145

1 mg RU 486

140.6

±

5 mg RU 486

145.6

±

±

147.5

±

1.4

155

2.9

2.4

160.9

2. 1

Values expressed are mean ± SEM (n= 8)
*(p< 0.05) compared with control.

±

±

1.7

3.1

Third
150

±

1.8

160

±

2.5

172.5

±

2.5

APPENDIX C

Table X
Effect of t h e M i n eralocorticoid Agonist Aldosterone a n d the
M i n e r alocorticoid Antagon i s t , Mespirenone Treat ment on Sys t o l i c B l o o d Pressure

Trea tment G r o u p s

0

First

Second

Third

Control

1 09 . 2 ± 2.4

1 1 0.3 ± 1 . 9

1 14.2 ± 3.6

1 1 5 ± 2.6

Aldosterone ( Al d o )

lOS.7 ± 3. 1

* 1 45 ± 2 . 6

* 1 6 1 . 6 ± 5.2

* 1 62.5 ± 4.S

Mespirenone ( M e s )

1 1 0.0 ± 2 . 7

1 24 . 7 ± 4 . 2

1 20.0 ± 3 . 3

1 1 4.0 ± 3 . 9

Ald o

+

1 0 Mes

109.0 ± 1 . 9

1 3 0. 1 ± 4 . 0

125.0 ± 2.6

1 26.6 ± 3 . 4

Aldo

+

20 M e s

1 0S . 2 ± 3 . 3

1 1 S.3 ± 1 . 9

1 15.0 ± 1.6

1 10.7 ± 1 . 9

Values expressed as mean ± S E M ( n = 6) .
* ( p < 0 . 0 5 ) compared t o control untreated a n i m a l s .

I-'
o
o
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APPENDIX D
Table XI
Effect of the Glucocorticoid Agonist, Dexamethasone, and the
Mineralocorticoid Agonist, RU 26752 Treatment on Systolic Blood Pressure
Week of Treatment
Second

Treatment Groups

0

Control

1 15.8

±

3.6

1 16.3

Dexamethasone (Dex)

1 16.0

±

2.8

* 153.1

±

2.6

* 158.2

±

4.2

Dex + RU 26752 (7.5 mg) 1 16.8

±

2.9

* 146.3

±

2.4

* 162.5

±

3.6

Dex + RU 26752 (15 mg) 1 15.6

±

2.5

* 154.4

±

2.9

* 15 1.9

±

2.9

First

Values expressed are mean ± SEM (n= 8)
*(P< 0.05) compared to control untreated animals.

±

4.2

1 18.8

±

4.3

APPENDIX E

Table XII

Effect o f t h e M i neralocorticoid Agonist Aldosterone a n d t h e
M i n e ralocorticoid Antagon i s t , M e s p i r e n o n e Tre a t m e n t o n Systolic B l o o d Pressure

Tre a t m e n t G ro u ps

0

First

Second

Third

Control

1 09 . 2 ± 2 . 4

1 10.3 ± 1 . 9

1 1 4 . 2 ± 3.6

1 1 5 ± 2.6

Al d o s t e ro n e (Al d o )

lOS.7 ± 3 . 1

* 1 45 ± 2 . 6

* 161.6 ± 5.2

* 1 62 . 5 ± 4 . S

M e s p irenone (Mes)

1 10.0 ± 2.7

1 24 . 7 ± 4 . 2

1 20.0 ± 3 . 3

1 1 4.0 ± 3.9

Ald o

+

10 Mes

1 09.0 ± 1 . 9

1 3 0. 1 ± 4 . 0

1 25 . 0 ± 2 . 6

1 26 . 6 ± 3 . 4

Ald o

+

20 M e s

l OS . 2 ± 3 . 3

l lS.3 ± 1 . 9

1 15.0 ± 1.6

1 10.7 ± 1.9

Values expressed as m e a n ± S E M ( n = 6) .
* (p < 0. 0 5 ) compared t o control untreated a n i m a l s .

f-'
o
N
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APPENDIX F
Table XIII
Effect of Glucocorticoid Agonist, Dexamethasone, and the Mineralocorticoid
Antagonist, Mespirenone (Mes), Treatment on Systolic Blood Pressure
Week of Treatment
First

Treatment Groups

0

Control

1 10

Dexamethasone (Dex)

1 10.9

±

3.6

* 146.0

±

4.2

* 142. 1

±

2.5

Dex + Mes (15 mg)

1 1 1.8

±

4.2

* 157.0

±

3.2

* 1 60.2

±

3.6

Dex + Mes (30 mg)

1 1 1.0

±

3.0

* 153.2

±

2.9

* 169.0

±

3.5

±

2.1

1 15.0

Values expressed are mean ± SEM (n= 8).
* (P < 0.05) compared to control untreated animals.

±

3.2

Second
1 17.0

±

3.3
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Table XIV

Effect of the Mineralocorticoid Antagonist, Mespirenone,
Treatment on Systolic Blood Pressure of Spontaneously Hypertensive Rats (SHR)
Week of Treatment
First
Second

Treatment Groups

o

Control

205.0

±

3.5

210.1

±

3.0

215.2

±

2.8

Mespirenone (2.5 mg)

196.2

±

1.9

200.0

±

2.2

198.3

±

3.6

Mespirenone (5 mg)

195.0

±

2.8

197.2

±

3.8

190.0

±

2.6

Values expressed are mean

±

SEM (n= 8).
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